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           INTRODUCTION      
India is perhaps the largest producer of medicinal herbs and is rightly called 
the  ‘Botanical  Garden  of  the  World’  there  are  very  few  medicinal  herbs  of 
commercial  importance,  which  are  not  collected  or  cultivated  in  this  country. 
Medicinal herbs have been in use for thousands of years,  in one form or another, 
under  the  indigenous  system  of  medicine  like  Ayurveda,  Siddha,  Unani,  since 
independence  in  1947,  India  has  made  tremendous  progress  in  agro  technology, 
process technology, standardization, quality control, research and development etc. 
    
Out now 2,25,000 species of plants known, about 35,000 are claimed to have 
medicinal  properties.   Today’s  estimation  indicate  that  about  80%  of  people  in 
developing countries still on traditional medicine based largely on species of plants 
and animals for their primary health care.  About 30% of the world wide sales of 
drugs are based on natural products.
India is one of the world’s 12th leading biodiversity centers with the presence 
of over  45,000 different  plant  species.   India’s diversity is  unmatched due to  the 
presence  of  sixteen  different  agro  climatic  zones  to  vegetation  zones,  25  biotic 
provinces & 426 biomes (habitat of specific species).
India has 15,000-18,000 species of flowering plants, 2500 algae, 23000 fungi, 
1600 types of lichen, 1800 varieties of bryophytes and an estimated 30 million types 
of microorganisms.
Of these about 15,000 - 20,000 plants have good medicinal value.  However, 
traditional communities use only about 7,000 - 7,500 for their medicinal values.
The siddha system of medicines uses about 600, Ayurvedha 700, Amuchi 600, 
Unani 700 and modern medicines about 50.
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According to 2004 United Nations Development Project (UNDP) report, the 
annual value of medicinal plants derived from developing countries is about $ 60 
billion.   There  are  78  major  modern  plant  based  drugs  on  world  market  &  the 
predicted 450 more potential drugs have an estimated of $ 180 billion.
Out of the large number of plants with known medicinal value and history of 
centuries  of  use in  traditional  medicine  very few have been exploited  in  modern 
medicine.  The  main  reason  being  lack  of  standardization,  isolation  and 
characterization of active principle. Recently World Health Organization (WHO) has 
taken an official interest on indigenous system of plant used particularly in natural 
sources like plants and animals1.
USEFULNESS OF PLANTS IN THERAPY    
Many of  the early plant  based drugs  such as  curare as  a  muscle  relaxant, 
Quinine  from  cinchona for  malaria,  Reserpine  from  Rauwolfia  serpentina for 
hypertension, Digitoxin from digitalis for heart ailments, the whole range of steroids 
from  diosgenin  which  is  obtained  from  Discorea  tubers,  Vincristence/vinblastine 
from Catharanthus roseus, the toxoids from Taxus brevifolia and  Taxus baccata as 
antimalarial are all still in use.  A number of new products are in the market or under 
development  for  indications  as  wide  ranging  as  flue,  herpes,  dermatitis,  wound 
healing, cancer, diabetes and Leucoderma.
APPROACH TO USE OF PLANTS IN MEDICINES
The  Indian,  Chinese,  Tibetan  and  other  Oriental  systems  use  plants  as 
medicines,  as  whole plants  or  as  their  extracts.   These systems also  use multiple 
plants  in  their  galenic  forms  with very elaborate  processing,  often  times  custom-
made, for specific disease condition and patients.  This approach has been justified by 
invoking immunomodulation as a possible mechanism of action with multiple plant 
component  and  synergistic  fashion  to  ensure  therapeutic  efficacy  and  minimal 
toxicity; plant and plant based drugs are non-toxic and have acceptable side effects.
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PLANTS AS SOURCES OF ACTIVE MOLECULES
An approach comparable  with the current  new discovery process is  to use 
plants as source of active molecules this approach has led to successful development 
of many molecules.  Many of them in common use even today Psoralen, Strychnine, 
Brucine,  Reserpine,  Quinine,  Quinidine,  Ajmaline,  Vinca  alkaloids,  Taxol, 
Artemesinin & a host of other products have come through this route. A number of 
semi-synthetic drugs have become major drugs for many disease conditions.  Thus 
the  entire  fields  of  hormonal  steroids  have  come  out  chemical  modification  of 
diasgenia, a product isolated from Dioscorea tubers or the Mexican yam. 
 The Chinese product Artemesinin has been converted to less toxic artmether 
& artether.  In all these cases, the discovery of new derivatives was made possible 
only due to the fact that original plants have shown activity,  even if it was low & 
hence was only a lead.
PLANTS AS LEADS TO DISCOVERY OF NEW DRUGS
Based on the strong and traditional knowledge based on the use of plants as 
therapeutic agents a rational approach is being developed to use medicinal plants as a 
lead for the discovery of active molecules.
Established drugs are also used as leads to synthesize new derivatives, which 
led to the well known and often unreasonably maligned me-too category of drugs. 
They are also termed as molecular manipulations or molecules roulette of existing 
drugs2.
 
INDIAN SYSTEM OF MEDICINE
“Indigenous  medicine”  is  used  to  refer  to  a  variously  defined  body  of 
knowledge that is concerned with healing but which can take many different forms. It 
can refer to the use of herbs and plants found locally and in highland Tigray as a 
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drink,  salve  or  inhalant;  bloodletting;  bone-setting;  cauterization;  the  utterance  or 
writing of special prayers for curing purposes; exorcism of spirits said to possess the 
body; and the use of holy water and other sanctified substances such as soil, ash, or 
sand. Different indigenous healers specialize in one or more of these types of healing. 
 Indian  system  of  Medicine  and  Homoeopathic  (AYUSH)  cover  both  the 
systems which originated in India and outside but got adopted in India in course of 
time.  These  systems  are  Ayurveda,  Siddha,  Unani,  Yoga,  Naturopathy  and 
Homoeopathy.  People are getting inclined for treatment through these systems due to 
lesser side effect in comparison to the modern medicines.
Ayurveda System of Medicine
Ayurveda  means  the  “Science  of  Life”.   The  knowledge  Ayurveda  was 
comprehensively documented in Charak Samhita  and Sushruta Samhita.  Ayurveda 
takes an integrated view of the physical, mental and spiritual and social aspects of 
human beings, each impinging on the others. The philosophy of Ayurveda is based on 
the theory of Panchmahabhutas (five-element  theory)  of which all  the objects  and 
living bodies are composed of.  The combination of the five elements are represented 
in  the form of  Tridosha  e.g.,  Vata (Ether+Air),  Pitta  (Fire),  Kaph (Water+Earth). 
These three ‘Doshas’ are physiological entities in living beings.
In Ayurveda diagnosis  included questioning,  inference  and examination  of 
Pulse, Urine, Faeces, Tongue, Auditory and Tactile perceptions, Eyes and body as a 
whole.  The treatment in Ayurveda system is individualized.  Treatment in Ayurveda 
has two components Preventive and Curative. 
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Siddha System of Medicine
 Siddha means achievements and Siddhars were saintly persons who achieved 
results in medicine. Siddha is largely therapeutic in nature.
  The diagnosis of disease involves identifying its causes. Identification of causative 
factors is through the examination of pulse, urine, eyes, and study of voice, color of 
the body, tongue and the status of the digestive system. 
The Siddha system is effective in treating chronic cases of liver, skin diseases 
especially “Psoriasis”.  The Siddha medicine which contains mercury, silver, arsenic, 
lead and sulphur have been found to be effective treating certain infectious diseases 
including venereal diseases. 
Unani System of Medicine
The Unani System of Medicine is based on its well established knowledge and 
practices relating to promotion of positive health and prevention of diseases. It is very 
rich, time tested with its therapies having no side effects.
The Unani  System emphasizes  the use of  naturally  occurring,  most  herbal 
medicine and a few of animal,  marine,  and mineral origin.  HK. Ajmal Khan has 
institutionalized  the  Ayurveda  &  Unani  system  of  medicine  and  advocated  the 
integration  with  science  in  understanding  the  Tibe-Unani  and  its  application  in 
treatment.  He discovered Asrol (Rawolfia serpentina) which established its efficacy 
in the treatment of high blood pressure.
The treatment comprises of three components, namely preventive, promotive 
and curative.  Unani system of Medicine is more efficacious in Rheumatic arthritis. 
Jaundice, Filariasis, Eczema, Sinusitis and Bronchial asthma etc. 
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 Its efficacy in the treatment  and management  of cardiac diseases is being 
researched.  Treatment  is  carried  out  in  four  forms  i.e.  Pharmacotherapy, 
Dietotherapy, Regimental Therapy and Surgery.
Homoeopathy
Homoeopathy  is  a  specialized  method  of  drug  therapy  of  curing  natural 
diseases by administration of drugs which has been experimentally proved to possess 
the power of producing similar artificial symptoms on healthy human beings.
Physicians  from the  time  of  Hippocrates  (around 400 B.C.)  observed  that 
certain substances could produce symptoms that they were used to treat.  However, it 
was a German doctor Dr. Christian Friedrich Samuel Hahnemann (1755-1843) who 
examined this observation more thoroughly and the emergence of Homoeopathy took 
place thereafter. 
The first principle similar similibus curentur, states that a medicine, which can 
induce a set of symptoms in healthy human   beings, would be capable of curing the  
similar set of symptoms in disease state. The second principle in single medicine at a 
time for a particular patient during the treatment on the basis of totality of symptoms. 
The third principle is minimum dose to be administered to a patient.  
  
Medicines
In Homoeopathy, medicines are prepared from natural sources viz. Vegetable, 
Mineral,  and  Animal  etc.   There  is  no  toxic  or  poisonous  effect  in  the  finished 
products of Homeopathic Medicines.
Strength of the system
Homoeopathy  has  its  own  areas  of  strength  in  therapeutics.  Its  curative 
capability  extends  to  allergic  manifestations,  auto-immune  disorders  and  viral 
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infections.   Many  Surgical,  Gynecological  &  Obstetrical  conditions,  ailments 
affecting  eyes,  nose,  ear,  teeth,  skin,  sexual  organs  etc  are  curable  through  the 
homoeopathic  treatment.   Behavioral  disorders,  neurological  problems,  metabolic 
disorders successfully treated by the physicians of this system. 
 Homoeopathy has effective answer to addiction to drugs, tobacco and alcohol and is 
highly efficacious in ridding of addicts and their craving for these noxious substances.
Yoga and naturopathy
Yoga is primarily a way of life propounded by patanjali in a systemic form.  It  
consists  of  eight  components,  namely,  restraint,  observance  of  austerity,  physical 
postures, breathing exercise, restraining of sense organs, contemplation, meditation 
and Samadhi.  These steps in the practice of yoga have potential for improvement of 
social and personal behaviour, improvement of physical health by encouraging better 
circulation of oxygenated blood in the body, restraining the sense organs and thereby 
inducing tranquility and serenity of mind.
Meditation can stabilize emotional changes and prevent abnormal functions of 
vital organs of the body.  Studies have shown that meditation not only restrains the 
sense organs but also controls the nervous system.
Naturopathy is a system of medicine widely practiced, globally accepted and 
recognized  by WHO. Naturopathy is  a  system of  man  building  in  harmony with 
constructive principles of Nature on physical, mental, moral and spiritual planes of 
living.   It  has  great  health  promotive  disease  preventive  and curative  as  well  as 
restorative potential.
Amchi system of medicine   
The Amchi system of Medicine is practiced in Ladakh district (J&K), Lahaul 
(Himachal Pradesh), Arunachal Pradesh, Sikkim and some regions of Himalayas. 
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The  system traces  its  origin  to  Ayurvedic  system of  India.   The  medical 
system since  its  delivery  by Lord  Buddha,  while  meditating  near  Bodh Gaya,  in 
course of time, had accumulated a huge literature and Amchi of great fame and repute 
were  produced.   Therapy  under  the  system  is  divided  into  treatment  by  herbs, 
minerals,  animal  organs,      spring  and mineral  water,  moxibustion  and spiritual 
powder.
The  Central  Council  for  Research  in  Ayurveda  and  Siddha  under  the 
Department  of  AYUSH  is  having  an  Amchi  Research  Unit  at  Leh  to  carry  our 
research and to conduct survey of local drugs in Leh & Ladakh3.      
LEUCODERMA AND ITS MANAGEMENT
Give me a blue sky, brown mountain, silver falls and green around, nothing 
more I want is a popular saying.  Nature is always wondered and admired at for its 
colorful beauty is being the main attraction.  
But the whiteness offered by skin disorder-Leucoderma is often depressing 
for all the sufferers.  Likewise in white skin people (even for leucoderma patient) hot 
sun UV rays penetrate more, putting them at risk for sunburn, skin cancer, etc. 
Leucoderma is a miserable acquired skin disorder, making skin white due to 
loss of the melanin pigment.  It is a non contagious disease. It is otherwise termed as  
Vitiligo.
Incidences and risk personalities 
Leucoderma is mostly restricted to the epidermis layer.  It can occur in any 
age group (infants to old age), sex and races.  Females are more commonly affected 
than males.  The most commonly affected areas are face, neck, back, wrist, and hand, 
groin, gentials, and armpits etc. i.e. dark places, places where folds occur or where 
friction takes place. 
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Causes  
Till now researchers have not identified any causative factor for leucoderma.  It can 
also be familiar i.e. hereditary factor also has some role in the prevalence of leucoderma. 
Being  emotionally  upset  may  also  precipitate  or  aggravate  the  complaint  in  certain 
circumstances.  Some suspect skin, lack of sun exposure, infection, etc. to be the reason for 
the problem. All these risk factors only, but the real cause is still obscure or unknown. 
 The main causes of leucoderma are said to be excessive mental worry, chronic or 
acute  gastric  disorder,  and  impaired  hepatic  function  such  as  jaundice,  worms  or  other 
parasites  in  the  alimentary  canal,  typhoid,  a  defective  perspiratory  mechanism,  and burn 
injuries. Heredity is also a well-recognized causative factor. 
Symptoms 
Leucoderma appears as odd, harmless, white spots or patches disturbing the 
appearance of the sufferer.  Mostly no other symptoms can be noted except whiteness 
of the skin.  The whiteness usually starts as a small discolored white or pale or brown 
spot which spreads and becomes whiter day by day and becomes milky white in the 
course of time. 
Prevention of spread
Check for any infective focus, worms, chemical, contact, etc if noted, they 
should be treated or eliminated start treatment early.  
Do’s
• Take medicines regularly in the early days itself so that complete cure can be 
achieved.
• Don’t worry about leucoderma, since effective treatment can arrest the course 
of the disease and cure it.
• Use umbrella when out in the hot sun.
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• Track all your eatables and habits to streamline all irritants or chemicals or 
sun exposure to arrest the spread of the disease. 
Don’ts
• Avoid working or roaming in the sun.
• Avoid fast food, citrus fruits, coffee, tea, cold drinks, alcohol, beer, non-veg, 
egg ect, It can causes spread of the disease.
• Avoid multiple drugs or drug cocktails.
• Avoid chemical soaps
Pathologically: 
 A defect in enzyme Tyrosinase is held responsible for vitiligo. According to 
some Dermatologists, it is a Trophoneurosis and Melatonin, a substance secreted at 
nerve endings inhibits Tyrosinase, thus interfering in pigment formation.
Clinical Presentation of Vitiligo 
Localized Type:
a) Focal - One or more macules in two single areas but not segmented.
b) Segmental - One or more macules in a dermatomal pattern.
c) Mucosal - Involvement of mucous membrane alone. 
Generalised Type: 
d) Acrofacial - Involvement of face and distal extremities.
e) Vulgaris - Scattered mascules in symmetrical or asymmetrical distribution. 
Universalis
 Total or nearly whole body involvement. 
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Who Is Affected by Vitiligo?
About 1 to 2 percent of the world's population, or 40 to 50 million people, 
have vitiligo. In the United States, 2 to 5 million people have the disorder. Ninety-
five percent of people who have vitiligo develop it before their  40th birthday.  The 
disorder affects all races and both sexes equally. Vitiligo seems to be more common 
in people with certain autoimmune diseases (diseases in which a person's immune 
system reacts against the body's own organs or tissues). 
These autoimmune diseases include hyperthyroidism (an overactive thyroid 
gland), adrenocortical insufficiency (the adrenal gland does not produce enough of 
the  hormone  called  corticosteroid),  alopecia  areata  (patches  of  baldness),  and 
pernicious anemia (a low level of red blood cells caused by failure of the body to 
absorb vitamin B12). Scientists do not know the reason for the association between 
vitiligo and these autoimmune diseases. However, most people with vitiligo have no 
other autoimmune disease.   Vitiligo may also be hereditary,  that  is,  it  can run in 
families. Children whose parents have the disorder are more likely to develop vitiligo. 
However, most children will not get vitiligo even if a parent has it, and most people 
with vitiligo do not have a family history of the disorder.  
How Is Vitiligo Diagnosed? 
If a doctor suspects that a person has vitiligo,  he or she usually begins by 
asking the person about his or her medical history.  Important factors in a person's 
medical history are a family history of vitiligo; a rash, sunburn, or other skin trauma 
at the site of vitiligo 2 to 3 months before depigmentation started; stress or physical 
illness; and premature graying of the hair (before age 35). In addition, the doctor will 
need to  know whether  the  patient  or  anyone  in  the  patient's  family  has  had any 
autoimmune diseases and whether the patient is very sensitive to the sun. The doctor 
will then examine the patient to rule out other medical problems.
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 The doctor may take a small sample (biopsy) of the affected skin. He or she 
may also take a blood sample to check the blood-cell count and thyroid function. For 
some patients, the doctor may recommend an eye examination to check for uveitis 
(inflammation of part of the eye). A blood test to look for the presence of antinuclear 
antibodies (a type of autoantibody) may also be done. This test helps to determine if 
the patient has another autoimmune disease. 
General Treatment 
There  is  no  scheduled,  conservative  treatment  at  all  with  rudimentary 
knowledge,  everyone  speaks  more,  but  none  of  the  internal  or  external  claims 
guarantee for solid cure.  No single therapy for leucoderma produces good result in 
all patients.
What Treatment Options Are Available?
The  goal  of  treating  vitiligo  is  to  restore  the  function  of  the  skin  and  to 
improve the patient's appearance. Therapy for vitiligo takes a long time. It usually 
must be continued for 6 to 18 months. The choice of therapy depends on the number 
of white patches and how widespread they are and on the patient’s preference for 
treatment. Each patient responds differently to therapy and a particular treatment may 
not work in everyone. 
TREATMENT OPTIONS FOR VITILIGO 
Medical Treatments 
Topical steroid therapy 
• Topical Psoralen photo chemotherapy 
• Oral Psoralen photo chemotherapy 
• Depigmentation
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Surgical Therapies
• Autologous skin grafts 
• Skin grafts using blisters 
• Micropigmentation (tattooing) and Autologous melanocyte transplants. 
Adjunctive Therapies
• Sunscreens 
• Cosmetics 
Counseling and support
Current treatment options for vitiligo include medical, surgical, and adjunctive 
therapies (therapies that can be used along with surgical or medical treatments). 
MEDICAL TREATMENTS 
TOPICAL STEROID THERAPY
Steroids may be helpful in repigmenting (returning the color to white patches) 
the skin, particularly if started early in the disease. Corticosteroids are a group of 
drugs similar to the hormones produced by the adrenal glands (such as cortisone). 
Doctors  often prescribe  a  mild  topical  corticosteroid  cream for  children  under  10 
years old and a stronger one for adults. Patients must apply the cream to the white  
patches on their skin for at least 3 months before seeing any results. It is the simplest  
and safest treatment but not as effective as Psoralen photochemotherapy. The doctor 
will closely monitor the patient for side effects such as skin shrinkage and skin striae 
(streaks or lines on the skin).  
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Psoralen Photochemotherapy
Psoralen photochemotherapy (Psoralen and ultraviolet A therapy, or PUVA) is 
probably the most beneficial treatment for vitiligo available in the United States. 
However, it is time-consuming and care must be taken to avoid side effects, 
which can sometimes be severe. Psoralens are drugs that contain chemicals that react 
with ultraviolet light to cause darkening of the skin. The treatment involves taking 
Psoralen by mouth (orally) or applying it to the skin (topically). This is followed by 
carefully  timed  exposure  to  ultraviolet  A (UVA) light  from a special  lamp or  to 
sunlight. Patients usually receive treatments in their doctor's offices so that they can 
be carefully watched for any side effects. Patients must minimize exposure to sunlight 
at other times. The goal of PUVA therapy is to repigment the white patches. 
Topical Psoralen Photochemotherapy 
Topical  Psoralen photochemotherapy often is  used for people with a small 
number of depigmented patches (affecting less than 20 percent of the body). It is also 
used  for  children  2  years  old  and  over  who  have  localized  patches  of  vitiligo. 
Treatments are done in a doctor's office under artificial UVA light once or twice a 
week. The doctor or nurse applies a thin coat of Psoralen to the patient's depigmented 
patches about 30 minutes before UVA light exposure. The patient is then exposed to 
an  amount  of  UVA  light  that  turns  the  affected  area  pink.  The  doctor  usually 
increases the dose of UVA light slowly over many weeks. Eventually, the pink areas 
fade and a more normal skin color appears. 
After each treatment, the patient washes his or her skin with soap and water 
and applies a sunscreen before leaving the doctor's office. 
There are two major potential side effects of topical PUVA therapy: 
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(1) Severe sunburn and blistering and (2) too much repigmentation or 
darkening of  the treated patches or the normal skin surrounding the vitiligo 
(hyperpigmentation).  Patients can minimize their chances of sunburn if they avoid 
exposure  to  direct  sunlight  after  each  treatment.  Hyperpigmentation  is  usually  a 
temporary problem and eventually disappears when treatment is stopped. 
Oral Psoralen Photohemotherapy
Oral PUVA therapy is used for people with more extensive vitiligo (affecting 
more than 20 percent of the body) or for people who do not respond to topical PUVA 
therapy. Oral Psoralen is not recommended for children under 10 years of age 
because of an increased risk of damage to the eyes, such as cataracts. For oral 
PUVA therapy,  the patient  takes a prescribed dose of Psoralen by mouth about 2 
hours before exposure to artificial UVA light or sunlight. The doctor adjusts the dose 
of light until the skin areas being treated become pink. Treatments are usually given 
two or three times a week, but never on two days in a row. For patients who cannot 
go to a PUVA facility Psoralen may be used with natural sunlight exposure, with 
careful instruction and frequent monitoring by the treating physician. 
Known side effects of oral Psoralen include sunburn, nausea and vomiting, 
itching,  abnormal  hair  growth,  and  hyperpigmentation.  Oral  Psoralen 
photochemotherapy may increase the risk of skin cancer.  To avoid sunburn and 
reduce the risk of skin cancer, patients undergoing oral PUVA therapy should apply 
sunscreen and avoid direct sunlight for 24 to 48 hours after each treatment. Patients 
should also wear protective UVA sunglasses for 18 to 24 hours after each treatment to 
avoid eye damage, particularly cataracts. 
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Depigmentation
Depigmentation involves fading the rest of the skin on the body to match the 
already white areas. 
For people who have vitiligo on more than 50 percent of their body, depigmentation 
may  be  the  best  treatment  option.  Patients  apply  the  drug  monobenzylether  of 
hydroquinone (monobenzone or Benoquin) twice a day to pigmented areas until they 
match the already depigmented areas. Patients must avoid direct skin-to-skin contact 
with other people for at least 2 hours after applying the drug. 
The major side effect of depigmentation therapy is  inflammation (redness 
and swelling) of the skin. Patients may experience itching, dry skin or abnormal 
darkening of the membrane that covers the white of the eye. Depigmentation is 
permanent  and  cannot  be  reversed.  In  addition,  a  person  who  undergoes 
depigmentation will always be abnormally sensitive to sunlight. 
SURGICAL THERAPY
All surgical therapies must be viewed as  experimental because their effectiveness 
and side effects remain to be fully defined. 
Autologous Skin Grafts
In autologous (use of a person’s own tissues) skin graft, the doctors removes 
skin from one area of a patient's body and attaches it to another area. This type of skin 
grafting is  sometimes  used for patients  with small  patches  of vitiligo.  The doctor 
removes sections of the normal, pigmented skin (donor sites) and places them on the 
depigmented  areas  (recipient  sites).  There  are  several  possible  complications  of 
autologous skin grafting. Infections may occur at the donor or recipient sites. 
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The  recipient  and  donor  sites  may  develop  scarring,  a  cobblestone 
appearance or a spotty pigmentation, or may fail to repigment at all. Treatment 
with grafting takes time and is costly, and most people find it neither acceptable 
nor affordable. 
Skin Grafts Using Blisters
In this procedure, the doctor creates blisters on the patient's pigmented skin by 
using heat, suction,  or freezing cold. The tops of the blisters are then cut out and 
transplanted to a depigmented skin area. 
The  risks  of  blister  grafting  include  the  development  of  a  cobblestone 
appearance, scarring, and lack of repigmentation. However, there is less risk of 
scarring with this procedure than with other types of grafting. 
Micropigmentation (Tattooing)
Tattooing implants pigment into the skin with a special surgical instrument. 
This  procedure works  best  for  the  lip  area,  particularly in people with dark skin; 
however, it is difficult for the doctor to match perfectly the color of the skin of the 
surrounding area. Tattooing tends to fade over time. In addition, tattooing of the 
lips may lead to episodes of  blister outbreaks caused by the Herpes Simplex 
Virus. 
Autologous Melanocyte Transplants
In  this  procedure,  the  doctor  takes  a  sample  of  the  patient's  normally 
pigmented skin and places it  in a laboratory dish containing a special  cell  culture 
solution to grow melanocytes. 
When the melanocytes in the culture solution have multiplied, the doctor transplants 
them  to  the  patient's  depigmented  skin  patches.  This  procedure  is  currently 
experimental and is impractical for the routine care of people with vitiligo. 
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ADJUNCTIVE THERAPY
Sunscreens
 People, who have vitiligo, particularly those with fair skin, should use a sunscreen 
that  provides  protection  from both the UVA and UVB forms of  ultraviolet  light. 
Sunscreen helps protect the skin from sunburn and long-term damage. Sunscreen also 
minimizes tanning, which makes the contrast between normal and depigmented skin 
less noticeable. 
Cosmetics
Some  patients  with  vitiligo  camouflage  depigmented  patches  with  stains, 
makeup, or self-tanning lotions. These cosmetic products can be particularly effective 
for people whose vitiligo is limited on exposed areas of the body. Dermablend, Lydia 
O'Leary, Clinique, Fashion Flair, Vitadye, and Chromelin offer makeup or dyes that 
patients may find helpful for covering up depigmented patches.
Tab 1 Medicinal plants used in Leucoderma4.
1 Abrus precatorius Linn 2 Acacia catechu Willd 
3 Acacia foprnesiana Willd 4 Acacia ferruginea DC
5 Acacia nilotica Del 6 Aconitum chasmanthum Stapf
7 Aconitum falconeri Stapf 8 Aconitum rugata Lam
9 Acorus calamus Linn 10 Adhatoda vasica Nees
11 Aglaia odoratissima Blume 12 Albizia amara Boivin
13 Albizia lebbek Benth 14 Allium cepa Linn
15 Allium sativum Linn 16 Alpinea galanga Willd
17 Alpinia khulanjan Sheriff 18 Alpinia officinarum Hance
19 Alstonia scholaris R Br 20 Altingea excelasa Noronha
21 Anararabtgus tristis Linn 22 Ammi majus linn
23 Anacardium occidentale Linn 24 Anacyclus pyrethrum DC
25 Amemone obustifolia D Don 26 Anethum sowa Roxb
27 Anthriscus cerifolium Hoffm 28 Apium graveolen Linn
29 Aquillaria agallocha Roxb 30 Argemone mexicana Linn
31 Aristolchia indica Linn 32 Artemisia siversiana Willd
33 Astragalus hamosus Linn 34 Atropa belladomma Linn
35 Azadirachta indica A juss 36 Bacopa montanum Linn
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37 Balanites aegyptica Del 38  Baleopermum montanum Muell-
Arg
39 Bambusa arundinaeca Willd 4o Barleria priotis Linn
41 Barleria strigosa Willd 42 Bauhimea variegate Linn
43 Blepharis edulis pers 44 Boswelia serrata Roxb
45 Brassica campestris Linn 46 Brassica nifra Koch
47 Butea monosperma (Lam) Kuntz 48 Calamus rotang Linn
49 Calotroppis gigantean R Br 50 Canscora decussate Roem et Sch
51 Capparis sepiaria Linn 52 Careya arborea Roxb
53 Carthamus tinctorius Linn 54     Carum carvi Linn         
55 Casearia esculenta Roxb 56 Cassia absus Linn
57 Cassia angustifolia vahl 58 Cassia tora Linn
59 Cedrus deodara (Roxb) Lour 60 Celastrus paniculata Willd
61 Centella asiatica Urban 62 Centipeda minima Br et Asch
63 Centratheryum anthelminitcum 64 Cephalandra indica Naud
65 Chenopodium album Linn 66 Cinnamomum zeylanicum Blume
67 Cissus adanta Roxb 68 Cissus setosa Roxb
69 Citrullus colocynthis Schrad 70 Cleome brachycarpa Vahl
71 Cleome chelidonni Linn 72 Cleome icosandra Linn
73 Clerodendron infortuatum Linn 74 Clitorea ternatea Linn
75 Commiphora agalocha Engl 76 Commiphora mukul Hook ex 
Stocks
77 Convolvulus scammonia Linn 78 Coptis teeta wall
79 Coriandrum sativum Linn 80 Corydalis govniana wall
81 Croton tiglium Linn 82 Cuminum cyminum Linn
83 Curcuma angustifolia Roxb 84 Curcuma aromatica Salisb
85 Curcuma caesia Roxb 86 Curcuma longa Linn
87 Curcuma zedoaria Rosc 88 Dalbergia sissoo Roxb
89 Datura metel Linn 90 Datura stramonium Linn
91 Delphinium denudatum Wall 92 Dioscorea bulbifera Linn
93 Dolichos biflorus Linn 94 Dolichos falcatus Klun
95 Drogea volubilis Benth 96 Ecballium elaterium ARich
97 Eclipta alba Massk 98 Eclipta erecta Lamk
99 Embelia ribes Burm f 100 Emblica officinalis Gaerth
101 Enhydra fluctuans Lour 102 Eruca sativa Mill
103 Euporbia meriifolia Linn 104 Evolvulus alsinoldes Linn
105 Fagonia cretica linn 106 Feronia limomia Swingl
107 Ficus carica Linn 108 Ficus hispida Linn
109 Ficus micrlcarpa E Vill 110 Ficus racemosa Linn
111 Ficus religiosa Linn 112 Ficus tsiela Roxb
113 Fumaria indica pugsley 114 Geranium wallichianum Sweet
115 Girardinia heteraphylla DC 116 Gisekia pharnaceildes Linn
117 Glorisa superba Linn 118 Gymnema sylevestre R Br
119 Gynocardia ldlrata R Br 120 Haemidesmus indicus R Br
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121 Heracleum candicans Wall 122 Heracleum canescens Lind
123 Heracieum pinnatumWild 124 Holarrhena antidysentrica Wall
125 Holostemma annulare K Schum 126 Hydnocarpus Kurzii Warb
127 Hyoscymus niger Linn 128 Indigofera tinctoria Linn
129 Ipomea hederacea Jacq 130 Ipomea reninflrmis Choisy
131 Ipomea raptans Plir 132 Iris versiclolr Linn
133 Lactuca scariola Linn 134 Lamprachemium microcephalum 
135 Lawsonia inermis Linn 136 Lepidium sativum Linn
137 Lolium femulentum Linn 138 Luffa acutangula Roxb
139 Lupinus albus linn 140 Macrotomea benthame DC
141 Macrotomea perennis Bois 142 Martynia annua Linn
143 Melia azardirach Bois 144 Melia acadirachta Linn
145 Meliotus alba Desr 146 Meliotus officinalis Desr 
147 Mentha sylvestris Linn 148 Mimosa pudica Linn
149 Moringa concanensis Nimmo 150 Mofinga oleifera Lam 
151 Murraya koenigii Spreng 152 Musa paradisiacal Linn
153 Mussaenda glabrata Hutich 154 Nardostachys jatamansi DC
155 Nelumbo mucifera Gaertn 156 Nerium odorum Soland 
157 Micotians rustica Linn 158 Nicotianatabacum Linn
159 Nigella sativa Linn 160 Nymphaea stellata Willd
161 Ocimum basilicum Linn 162 Ocimum samctum Linn
163 Onosma bracteatum Will 164 Onosma echilides Linn
16
5
Operculiana turpethum satiba 
Linn
166 Opuntia dillunii Haw
16
7
Origanum majorana Linn 168 Oroxylon indicum Vent
16
9 
Orthosiphon pallidus Royle 170 Ougeinia oojeinensis Hochr
17
1
Oxystelma esculenta R Br 172 Paederia foetida Linn
17
3
Pandanus tectorius Sol 174 Paris polyphylla Smith
17
5
Pentatropis cynachoides R Br 176 Phaseolus radiatus Lour
17
7
Picrorrhiza kurroa Royle ex Behth 178 Pinus sylvestris Linn
17
9
Piper longum Linn 180 Plantanus orientalis Linn
18
1
Plumbago indica Linn 182 Plumbago zeylanica Linn
18 Pongamia pinnata Merr 184 Prospis juliflora DC
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18
5
Prunus amygdalus Stok 186 Prunus cerasoidea D Don 
18
7
Prunus perrica Batsch 188 Psoralea corylifolia Linn
18
9
Pterocarpus  marsupium Roxb 190 Punica granatum Linn
19
1
Randia dumetorum Lam 192 Ranunculus scleratus Linn
19
3
Raphanus sativus Linn 194 Rheum emodi Wall
19
5
Ricinus communis Linn 196 Rubia cordifolia Linn
19
7
Rumex besicarium Linn 198 Sapindus mukorossi Gaerth 
19
9
Sasbania sesban Merr 200 Ssussurea lappa Clarke 
20
1
Semecarpus anacardium Linn 202 Solanum indicum Linn
20
3
Solanum melongena Linn 204 Solanum nigrum Linn
20
5
Sphaeranthus indicus Linn 206 Spinacea oleracea Linn
20
7
Strychmos nux vomica Linn 208 Swertia chirata Buch Ham
20
9
Tamarix articulate Vahl 210 Tamarix indica Linn
21
1
Tamarix troupii Hole 212 Tecomelia undulate Seem
21
3
Tectona grandis Linn 214 Terminalia arjuna Wright &Arn
21
5
Terminalia belerica Rlxb 216 Terminalia chebula Retz
21
7
Terminalia citrine roxb 218 Thevetia neriifolia Juss
21
9
Tricholepis glaberrima DC 220 Trichosanthes cucurmeriana Linn
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1
Trigonella foenumgraecum Linn 222 Urginea indica Kunth
22
3
Urtica dioica Linn 224 Uritica parviflora Rlxb
22
5
Vicia faba Linn 226 Viola serpens Wall
22
7
Viola tricolor Linn 228 Vilex megundo Linn
22
9
Vitex triflioa Linn 230 Wedelia calendulacea Less
23
1
Widhania somnifera Dunal 232 Wrightia tinctoria R Br 
23
3
Xanthium stumarium Linn 234 Zanthoxylum acanthopodium DC
23
5
Zanthoxulum alatum Roxb 236 Zanthoxylum oxyphyllum Edgew
23
7
Zingiber officinale Rosc
MICROSPONGE DRUG DELIVERY SYSTEM (MDS)
During the few years,  in  pharmaceutical  research much attention  has been 
given  to  the  controlled  release  of  Topical  drugs.  By  the  use  of  this  approach, 
controlling the therapeutic efficacy of these drugs, reduction in the total dose needed 
and a reduction in the side effects can be provided. 5   For this purpose, Microsponges 
are one of the systems which are in trial for controlled drug delivery. Microsponges 
are porous, polymeric microspheres that are used mostly for topical and recently for 
oral administration.  Microsponges are microscopic spheres capable of absorbing skin 
secretions,  therefore reducing oiliness and shine from the skin.  Spherical  particles 
composed of clusters of even tinier spheres are capable of holding four times their 
weight in skin secretions.  The particle size ranges between 5-300 micrometer6. 
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The  most  closely  related  systems  are  Microcapsules  and  Microspheres. 
Microcapsules  are  spherical  particles  containing  an  active  agent  in  the  core, 
surrounded  by  a  polymeric  membrane.   Microspheres  are  spherical  particles 
containing the active agent dispersed in a polymeric matrix.  
The major distinguishing feature between Microsponge and Polytrap systems 
and  Microcapsules,  or  Microspheres,  is  structure  of  Microsponge  and  Polytrap 
systems are highly porous, while Microspheres or Microcapsules are solid particles 
with no internal voids.    
A variety of active agents can be entrapped in a single Microsponge system 
and to release them at desired rates. The Microsponge system can prevent excessive 
accumulation of ingredients within the epidermis and the dermis. Potentially, the 
Microsponge system can reduce significantly the irritation of effective drugs without 
reducing their efficacy. Further these porous microspheres with active ingredients can 
be incorporated in to formulations such as creams, lotions and powders.
 Microsponges consisting of non-collapsible  structures  with porous surface 
through active ingredients are released in a controlled manner. This delivery system 
can be incorporated into conventional  dosage forms such as creams,  lotions,  gels, 
ointments, and powder and share a broad package of benefits.
Advantages of MDS 7
 Advance oil control – absorbs up to 6 times its weight without drying.
  Extended release – continuous action up to 12 hours.
 Reduced irritation – better tolerance means broader consumer acceptance. 
 Improve product aesthetics – gives product an elegant feel.
 Improve the stability – thermal, physical and chemical.
 Allow incorporation of immiscible.
 Allow for novel product form.
 Improve the material processing.
 Conversion of indigenous drugs in to Novel drug delivery system
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Method of preparation 
Polymerization
 The porous microspheres are prepared by Suspension Polymerization method 
in liquid-liquid systems. 12, In this preparation, the monomers are first dissolved along 
with  active  ingredients  in  a  suitable  solvent  solution  of  monomer  and  are  then 
dispersed in the aqueous phase, which consist  of additives (surfactant,  suspending 
agents, etc. to aid in formation of suspension). 
The polymerization is then initiated by adding catalyst or by increasing temperature 
or irradiation. The various steps in the preparation of Microsponge are summarized as
- Selection of monomer or combination of monomers
- Formation of chain monomers as polymerization begins
- Formation of ladders as a result of cross linking between chain monomers
- Folding of monomer ladder to form spherical particles
 - Agglomeration of Microspheres which give rise to formation of bunches of  
      Microspheres 
-    Binding of bunches to form Microsponges 
   The polymerization process leads to the formation of a reservoir type of system,  
which opens at the surface through pores. In some cases an inert liquid immiscible 
with water but completely miscible with monomer is used during the polymerization 
to form the pore network. After the polymerization the liquid is removed leaving the 
porous  microspheres,  i.e.,  Microsponges.  Impregnating  them  within  preformed 
Microsponges then incorporates the functional substances. Some times solvent may 
be  used  for  faster  and  efficient  incorporation  of  the  active  substances.  The 
Microsponges act as a topical carriers for variety of functional substances, e.g. anti 
acne, anti inflammatory, anti purities, anti fungal, rubefacients, etc6. 
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Quasi – Emulsion solvent diffusion method
 Microsponges prepared by a quasi-emulsion solvent diffusion method using 
an external phase of containing distilled water and polyvinyl alcohol (PVA) 72 000. 
The internal phase consisted of drug, ethyl alcohol, polymer and triethylcitrate (TEC)8 
,  Which  is  added at  an  amount  of  20% of  the  polymer  in  order  to  facilitate  the 
plasticity9. At first, the internal phase was prepared at 60°C and added to the external 
phase at room temperature. After emulsification, the mixture is continuously stirred 
for 2 hours. Then the mixture is filtered to separate the Microsponges. The product is 
washed and dried by vacuum oven at 40°C for 24 hours. 
Variables during in the preparation 10 
o Drug and Polymer ratio
o Effect of stirring time
o Effect of stirring speed
o Effect of composition of internal and external phase
o Viscosity 
POLYMERS FOR DRUG DELIVERY
Role of polymers 11
The polymer can protect the drug from the physiological environment and 
hence improve its stability in vivo.  By altering the polymer structure in certain ways 
the rate at which the drug release can be controlled.  Design the polymers that are 
more hydrophobic will cause the drug to be released slowly, while a polymer that is 
less hydrophobic will release its drug faster.
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Characteristic of ideal polymer 12
1. It should be chemically inert and free from leachable impurities.
2. It should have good mechanical strength.
3. It should be easy and inexpensive to fabricate.
4. It should be easily sterilized.
5. It should demonstrate acceptable shelf life.
Drug release mechanism 13
Two broad categories of polymer system have been studied.  The reservoir 
device involves the encapsulation of a drug with in the polymer shell, while the 
matrix device describes a system in which a drug is physically entrapped with in a 
polymer net work.  The drug will be released over time either by diffusion out of the 
polymer matrix or by erosion (due to degradation) of the polymer or by a combination 
of two mechanisms.
Polymers have been classified broadly as 13
 Natural polymers                 -    Albumin,   Starch,  Dextran,   Gelatin
                                                               Fibrinogen, Chitosan ect.
 Synthetic polymers              -     Polymethyl   methacrylate,   Polymethyl
                                                               methacrylate,  Copolymers:  Polymethyl
                                                               Cyanoacrylate, Polyacrylamide, Poly
                                                               acryl starch, Poly lactic acid ect.
Polymers are further classified on the basis of their interaction with water.
Non-biodegradable polymers
They are inert in the environment of use and eliminated intact from the site of 
administration and is the rate limiting factor.  
Eg: Polyethlene Vinyl Acetate (PVA). Poly Dimethl Siloxane (PDS), Poly Urethane 
(PU), Ethyl Cellulose (EC), Cellulose Acetate (CA) etc.
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Hydro Gels
These type of polymers swell but do not dissolve when brought into contact 
with water. They are inert and remover intact from the site of administration. 
Eg: Poly Hydroxyl Ethyl Metha Acrylate (PHEMA), cross linked Poly Vinyl Alcohol 
(PVA), cross linked Poly Vinyl Pyrrolidone (PVP), Polyacrylamide, Dextran.
Soluble polymers 
 These are moderate weight uncross-linked polymers that, dissolve in water.
  Eg: Poly Ethylene Glycol (PEG), Hydroxy Propyl Methyl Cellulose, Methocel and 
copolymers of methamers of methacrylic acid, Acrylic methyl acid methyl ester 
(Eudragit L).
Biodegradable polymers
These  slowly  disappear  from  the  site  of  administration  in  to  a  chemical 
reaction like hydrolysis. 
Eg: Poly Lactic Acid (PLA), Poly Glycolic Acid (PGA), Poly Capro Lactone (PCL) 
12. 
Polymers used in MDS 
• Polymethacrylate
• Ethyl cellulose
Evaluation of MDS (Microsponge Drug delivery System)  14 – 16 
Prepared Microsponges are generally analyzed by following parameters
 Polymer composition
 Particle size
 Surface topography 
 Pore diameter
 Drug content
 Loading efficacy
 Product yield
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 Drug release studies  
Drugs explored in Microsponge delivery 7
•  Ketoprofen
•  Benzyl peroxide
• Retinol
• Fluconazole
•  Ibuprofen
• Tretinoin
• Trolamine
MICROSPONGE INCORPORATED IN TO TOPICAL DRUG DELIVERY
Topical Drug Delivery 
Topical semi – solids are preparations designed to exert local activity when 
applied to the skin or mucous membranes. The main medicinal applications of semi – 
solids  are  as  protective,  emollient,  and  therapeutic  agents.   They  include  such 
dosage forms as creams, gel, ointments, pastes and poultices17. 
Tab 2 Commercial Microsponge Formulations 7
GELS
NAME DRUG REMARKS/USE
Afirm 3X 
  
Retinol Design to treat photodamaged skin 
EpiQuin[TM]
Vitamin A         Gradual treatment of ultraviolet induced 
dyschromia and discoloration                                    
RnUn-A Micro 
  
Tretinoin For the treatment of acne 
vulgaris 
Curan[R] 5-flourouracil    For actinic keratois 
MicroPeel[R] 
  
Salicylic acid    Freeing the skin of all dead cells and stimulating 
the skin renewal process.
Sprtscream[R] 
XS               
Trolamine For the temporary relief of pain associated with 
musculoskeletal soreness and discomfort
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Gels are transparent or translucent semi – solid or solid preparation consisting 
of solutions or dispersions of one or more active ingredients in suitable hydrophilic or 
hydrophobic bases. They are made with the aid of gelling agent.  Usually gels exhibit 
pseudoplastic  flow properties  and  those  made  with  synthetic  or  semi  –  synthetic 
polymers with a high degree of cross – linking have relative high yield value and low 
viscosity.  
Product tends to be smooth, elegant, and produce cooling effect because of 
evaporation of water.  They may also dry out to form films.  Films adhere well to the 
skin and are usually easily removed by washing.  
Gels  (sometimes  called  Jellies)  are  semisolid  systems  consisting  of  either 
suspensions  made  up  of  small  inorganic  particles  or  large  organic  molecules 
interpenetrated by a liquid. Where the gel mass consists of a network of small discrete 
particles,  the gel is  classified as a  two-phase system (e.g.,  Aluminum Hydroxide 
Gel). In a two-phase system, if the particle size of the dispersed phase is relatively 
large, the gel mass is sometimes referred to as a magma (e.g., Bentonite Magma).
 Both gels and magmas may be thixotropic,  forming semisolids on standing 
and  becoming  liquid  on  agitation.  They  should  be  shaken  before  use  to  ensure 
homogeneity and should be labeled to that effect. 
Single-phase gels consist  of organic macromolecules  uniformly distributed 
throughout a liquid in such a manner that no apparent boundaries exist between the 
dispersed  macromolecules  and  the  liquid.  Single-phase  gels  may  be  made  from 
synthetic macromolecules (e.g., Carbomer) or from natural gums (e.g., Tragacanth). 
The  latter  preparations  are  also  called  mucilages.  Although these  gels  are 
commonly aqueous, alcohols and oils may be used as the continuous phase. 
For example, mineral oil can be combined with a polyethylene resin to form 
an oleaginous ointment base. Gels can be used to administer drugs topically or into 
body cavities (e.g., Phenylephrine Hydrochloride Nasal Jelly)18.
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SKIN STRUCTURE
The skin is one of the most extensive organs of the human body covering an 
area  of  about  2m2 in  an  average  human  adult.  This  multilayered  organ  receives 
approximately one – third of all blood circulating through the body.
The integument is composed of skin and its associated tissues  sweat glands, 
sebaceous glands,  hair, and  nails.  It is  largest organ of the body (6% of the body 
weight).Covers the entire body continuous with the digestive system (lips and anus), 
respiratory system (nose), and urogenital system (urethra).
SKIN FUNCTION 
1) Serves as a barrier to physical, biological, and chemical agents and 
to radiation 
2)  Prevents desiccation
3)  Regulates  body  temperature  (thermoregulation) by  evaporative 
cooling  (perspiration),  heat  radiation  at  the  surface  of  the  body 
(blood circulation), and   serves as insulation (a minor function in 
humans) 
4)  Site of excretion through sweat glands 
5)  Photochemical production of vitamin D 
6)   Serves as a sensory organ 
Skin is composed of two primary layers 
The epidermis is the ectodermally derived outer layer composed of keratinized 
stratified squamous epithelium.
The dermis is the mesodermally derived layer of dense irregular collagenous 
connective tissue that underlies and interdigitates with the epidermis. The hypodermis 
is a loose connective tissue containing varying amounts of adipose that underlies and 
supports the skin, it is the superficial fascia that covers the entire body. 
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Fig 1 Structure of Skin
THE EPIDERMIS:
 The  epidermis  is  an  epithelium comprised  of  keratinocytes undergoing  a 
program of sequential differentiation. The four major layers arise from the sequential 
differentiation of cells migrating from the basal layer to the surface. 
  The  basal layer (stratum basale) is the deepest layer; it sits on the dermis. 
This layer is comprised of a single layer of mitotically active cuboidal or columnar 
epithelia. This is a major region of  mitotic activity.  Roughly half of the basal cell 
keratinocytes  are  mitotically  active.  The  others  become  active  after  wounding.  
Hyperproliferative diseases like psoriasis result from an inbalance of stimulatory and 
inhibitory growth factors acting on these cells. Basal cells are attached to each other 
by  desmosomes that  contain  cadherins. Basal  cell  layers  attach  to  the  basement 
membrane (basal  lamina)  on which they reside  via  hemidesmosomes that  contain 
integrins.
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 Desmosomes and hemidesmosomes anchor intermediate filaments, which are 
comprised of  keratins  in epithelial cells, to the cell surface. Two types of keratins, 
type I keratins, which are acidic and type II keratins, which are basic, are required to 
form an  intermediate  filament.   In  epidermis,  different  pairs  of  keratin  genes  are 
expressed as the cells migrate upward from the basal layer and proceed through their 
differentiation program. For example,  keratin  5 and 14 are expressed in the basal 
layer, while keratins 1 and 10 are found in the spinous layer.   
 The spinous layer (stratum spinosum) is the thickest layer of epidermis. The 
cells in this layer arise from the migration from the basal layer and lose their adhesion 
to the basement membrane and adhere to other keratinocytes. Some cells in this layer 
are also mitotically active. The cells in this layer attain a more flattened shape and 
have  increased  amounts  of  keratin  containing  intermediate  filaments  and 
desmosomes. 
The  granular layer (stratum granulosum) is characterized by the presence of 
keratohyalin  granules among  the  keratin  filaments;  it  consists  of  3-5  layers  of 
flattened  keratinocytes.  Keratohyalin  granules  contain  the  protein  filaggrin,  which 
serves to bundle the keratin filaments together. This is the most superficial layer of 
the epidermis that still has nuclei. 
These  layers  (and  the  upper  spinous  layers,  to  a  lesser  degree)  contain 
membrane coating granules (lamellar granules). 
The cornified layer (stratum corneum) is the most superficial layer of skin and 
is composed of layers of dead cells.   There is a sharp transition between the granule 
layer and cornified layer.   Keratin filaments are highly crosslinked by the formation 
of S-S bonds and the bundling activity of keratohyalin. Membrane coating granules 
are  exocytosed  into  the  intracellular  space.  The  high  lipid  content  forms  a 
permeability barrier for water retention and resistence.  This layer provides 98% of 
the water retention ability of the epidermis. The plasma membrane becomes thick, 
due  to  the  deposition  and  crosslinking  (via  transglutaminase,  an  enzyme  that 
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covalently  links  glutamine  to  lysine)  of  proteins,  like  involucrin,  along  its  inner 
surface to form the cornified envelope. 
These  cells  lack  nuclei  and  other  organelles  but  have  numerous  keratin 
filaments.  Cells farther from the skin surface have desmosomes, while those nearer 
to the surface do not and will be sloughed. Epidermis turns over about every 14-30 
days depending on the region of skin. Different areas of skin show differing thickness 
of epidermis.  
1. The epidermis thickens in response to use (abrasion). 
2. The dryness of skin serves as an inhospitable environment for 
growth of microorganisms.
 THE DERMIS: 
The  dermis is  a dense,  irregular,  mesodermally derived,  connective  tissue, 
composed of collagen (mostly type I), elastin, and glycosaminoglycans.  It is much 
thicker than the epidermis, comprising 80-90% of the total dermis and epidermis.
It contains extensive vasculature, neurons, smooth muscle, and fibroblasts.  It 
is the principal mechanical barrier of skin.  Its networks of elastic fibers function to 
support  the  epidermis  and  bind  the  skin  to  the  deeper  hypodermis.   The  dermis 
contains two layers, the papillary layer and the reticular layer. The papillary layer 
is a loosely woven, superficial  connective tissue region that interdigitates with the 
epidermal ridges and the deeper reticular layer.
 A key feature of this layer is the dermal ridges (dermal papillae) that extend 
up  in  ridges  into  the  overlying  epidermis  and  interdigitate  with  epidermal 
invaginations (epidermal ridges). The dermal ridges contain Meissner’s corpuscles, 
encapsulated nerve endings, and capillary loops that provide nutrients to the avascular 
epidermis.   A  basal  lamina  supports  the  basal  layer  of  the  epidermis.  Thin 
collagenous and elastic fibers underlie the basal lamina. Fibroblasts, mast cells, and 
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macrophages  occupy  the  papillary  layer.  The  reticular  layer  resides  below  the 
papillary layer. 
It  is  comprised  of  coarse  collagenous  and  elastic  fibers  (irregular  dense 
connective  tissue)  and  relatively  few  cells.Arteries  and  veins  run  through  the 
hypodermis  and  branch  upward  to  form  plexuses  of  anastomosing  vessels.  The 
cutaneous  plexus  resides  at  the  junction  of  the  hypodermis  and  dermis,  and  the 
papillary  plexus  resides  just  beneath  the  epidermis.    This  system  provides 
nourishment to the dermis and by diffusion to the epidermis, which is avascular. The 
vascular  system  functions  in  thermoregulation.  Blood  flow  is  controlled  by 
contraction of arterioles and venules to send blood through the capillary bed for heat 
radiation.  In some regions of skin, arteriovenous anastomoses, or shunts, can send 
blood directly from the arterioles to venules in order to reduce heat loss.
The dermis contains neuronal elements for touch, pain, itch, and temperature 
reception. 
1. Some receptors are free nerve endings. 
2. Other nerve endings associate with Merkel cells in the 
epidermis. 
3. Meissner’s corpuscles reside in the dermal papillae and 
function as mechanoreceptors in touch perception.
4. Pacinian corpuscles are found deep in the dermis (and in the 
hypodermis) and function in pressure sensation19.
   LITERATURE SURVEYED
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LITERATURE SERVEYED OF MICROSPONGE
 Çomoğlu et.al5  Reported the Effect of Different Polymers on Microsponge 
Formation.  By the use of this approach, controlling the therapeutic efficacy of 
these drugs, reduction in the total  dose needed and a reduction in the side 
effects  can  be  provided.  The  Microsponges  were  prepared  by  emulsion-
solvent  diffusion  method  using  different  polymers  such as  ethyl  cellulose, 
Eudragit RS 100 and Eudragit RS 100 and ethyl cellulose mixtures at different 
ratios.
 Patel Geeta et.al7 Reported Use of a Microsponge in drug delivery systems. 
The  Microsponge delivery system is a unique technology for the controlled 
release of topical agents and consists of macroporous beads, typically 10-25 
microns in diameter, loaded with active agent. When applied to the skin, the 
Microsponge releases  its  active  ingredient  on  a  time  mode  and  also  in 
response  to  other  stimuli  (rubbing,  temperature,  pH,  etc).  Microsponge 
technology  offers  entrapment  of  ingredients  and  is  believed  to  contribute 
towards  reduced  side  effects,  improved  stability,  increased  elegance,  and 
enhanced formulation flexibility.
 Jelvehgari et.al.10 Carried out preparation, characterization and release studies 
of Benzoyl  peroxide (BPO) Microsponge drug delivery prepared by quasia 
emulsion  solvent  diffusion  method.  The  aim  of  the  present  study  was  to 
produce  ethylcellulose  microparticles  containing  BPO  which  were  able  to 
control  the  release  of  BPO  to  the  skin  and  reduces  the  side  effect  of 
commercial BPO such as irritation and percutaneous absorption. Generally, an 
increase in the ratio of drug: polymer resulted in a reduction in the release rate 
of BPO from Microsponges.
 Mine  Orlu  et.al20  Prepared  a  Novel  colon  specific  drug  delivery  system 
containing flurbiprofen (FLB) Microsponges. The colon specific formulations 
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were  prepared  by  compression  coating  and  also  pore  plugging  of 
Microsponges with pectin:  hydroxypropylmethyl  cellulose (HPMC) mixture 
followed by tabletting.
   Comoglu et.al21  Carried out the  enhancement of ketoprofen bioavailability 
by  formation  of  microsponge  tablets.   An  in  vivo  study  was  designed  to 
evaluate  the  pharmacokinetic  parameters  and  to  compare  them  with  the 
commercially available ketoprofen retard tablets containing the same amount 
of  the  active  drug.   The  new  modified  release  tablets  showed  a  slower 
absorption rate and peak levels were reached 8 h after administration.
  Tansel  Çomoglu  et.al22  Reported  the  effects  of  pressure  and  direct 
compression on tabletting of Microsponges.  Microsponge delivery is used 
both  oral  and  topical  purpose.  Ketoprofen  was  used  as  a  model  drug  for 
systemic  drug  delivery  of  Microsponges. Microsponges  were  prepared  by 
quasi-emulsion solvent diffusion method with Eudragit RS 100 and afterwards 
tablets  of  Microsponges  were  prepared  by  direct  compression  method. 
Different pressure values were applied to the tablet powder mass in order to 
determine the optimum pressure value for compression of the tablets.
 Nokhodchi   et.al23  Reported  Factors  affecting  the  morphology  of  benzoyl 
peroxide  Microsponges. Benzoyl  peroxide  (BPO)  is  primarily  used  in  the 
treatment  of mild  to  moderate  acne.  However,  its  application  is  associated 
with  skin  irritation.  It  has  been  shown  that  encapsulation  and  controlled 
release of BPO could reduce the side effect while also reducing percutaneous 
absorption  when  administered  to  the  skin.   The  SEM  (Scanning  Electron 
Microscopy) micrographs of the BPO Microsponges enabled measurement of 
their size and showed that they were spherical and porous. Results showed 
that the morphology and particle size of Microsponges were affected by drug: 
polymer ratio, stirring rate and the amount of emulsifier used.
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 Chadawar   et.al24  Reported Microsponge delivery system.  Microsponges are 
polymeric delivery systems consisting of porous microspheres having a size 
range in between 5 to 300 micron depending upon the degree of smoothness 
or after feel required for the end formulations.  The present review introduces 
Microsponge  technology  along  with  its  synthesis,  characterization, 
programmable parameters and release mechanism of MDS. MDS can provide 
increased efficacy for topically active agents with enhanced safety, extended 
product stability and improved aesthetic properties in an efficient and novel 
manner.
  Leyden et.al25 Carried out comparison of the efficacy and tolerability of once 
daily tazarotene 0.1% gel and tretinoin 0.1% Microsponge gel were evaluated 
in a multicenter,  double-blind,  randomized,  parallel-group study in patients 
with  mild-to-moderate  inflammatory  facial  acne  vulgaris.   Tazarotene  was 
observed to have greater efficacy and comparable tolerability and to be a cost-
effective alternative to tretinoin 0.1% Microsponge gel.
  Shigemitsu  Iwai  et.al26 Reported Biodegradable  polymer  with  collagen 
Microsponge  serves  as  a  new  bioengineered  cardiovascular  prosthesis. 
Biodegradable  materials  with  autologous  cell  seeding have  attracted  much 
interest as potential cardiovascular grafts.  The poly(lactic-co-glycolic acid)–
collagen Microsponge patch with and without precellularization showed good 
histologic findings and durability. 
 Pearl et.al27   Performed a Microsponge Formulation of Hydroquinone (HQ) 
4% and Retinol 0.15% in the Treatment of Melanoma and Post inflammatory 
Hyperpigmentation. Microsponges  were  used  to  release  HQ  gradually  to 
prolong exposure to treatment and to minimize skin irritation. The safety and 
efficacy of this product were evaluated in a 12-week open label study.  In this 
open-label study, micro entrapped HQ 4% with retinol 0.15% was safe and 
effective.
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LITERATURE SURVEYED OF PSORALEN 
 Hsu Y-T et.al28 Reported the presence of  three isoflavonoid  compound in 
Psoralea corylifolia.  The method proved to be sensitive, specific, accurate 
and precise for the determination of daidzein, genistein and biochanin A in 
Psoralea corylifolia.  
 Guo WS et.al29 Carried out selection  isolation of Iso Psoralen from crude 
extract  of  Psoralea  corylifolia.L  by  using  inclusion  method  of  host  guest 
molecules.  
 Yadava  RN et.al30  Reported  a  new biologically  active  flavonol  glycoside 
from Psoralea corylifolia.
 
 Liu  ZL  et.al31  carried  out  extraction  and  purification  of  Psoralen  from 
Psoralea corylifolia.  To establish a method for extracting Psoralen from the 
seed of Psoralea corylifolia.
 Rajendra  Prasad  N  et.al32  Reported  antidermatophytic  activity  of  extract 
from  Psoralea  corylifolia correlated  with  the  presence  of  a  flavonoid 
compound.  The extract showed several degree of antifungal activity against 
Trichophyton rubrum and Microsporum gypseum the disc diffusion method 
on a Sabouraud dextrose agar medium.
 Said.A  et.al33  Carried  out  Psoralens  percutaneous  permeation  across  the 
human whole skin and epidermis in respect to their polarity. 
46
 Arabzadeh  et.al. 34  Reported  mechanism  of  8  –  methoxy  Psoralen  DNA 
interaction in the dark.  The interaction of 8 – methoxy Psoralen with calf 
thymus DNA was studied in darkness at 25 ºC and pH 7.4.
 Said et.al. 35 Carried out wettability of Psoralen powder influence of bile salts 
on their contact angles and surface free energy components.
 Rama Sastry CV et.al36 Reported A study of Psoralen photochemotherapy 
with topical tar in the management of psoriasis vulgaris.
  Bhatnagar A 37et.al Carried out Psoralen and ultraviolet A and narrow-band 
ultraviolet  B  in  inducing  stability  in  vitiligo,  assessed  by  vitiligo  disease 
activity score: an open prospective comparative study.
 Gomes AJ 38 et.al Carried out Identification of Psoralen loaded PLGA poly 
(DL-lactide-co-glycolide) microspheres in rat skin by light microscopy.  Drug 
delivery  systems  involving  the  use  of  polymers  are  widely  studied  and 
discovery of biocompatible polymers has become the focus of research in this 
area. Psoralen loaded poly PLGA microspheres to be used in PUVA therapy 
(Psoralen and UVA irradiation (ultraviolet A, 320-400 nm) of psoriasis were 
identified in paraffin sections by histological analysis.  The Psoralen loaded 
PLGA microspheres were prepared using the solvent evaporation technique
 Srinivas CR 39 et.al Reported Psoralens are chemical compounds derived from 
certain plants such as ammimajus found in Egypt and Indian plant babachee 
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which is also called as Psoralea corylifolia. Psoralen has been found in more 
than 30 plants such as lime, lemon, bergamot, parsley, celery, fig and cloves. 
The medical  use of these plants in the treatment  of vitiligo by the ancient 
Egyptians dates back to as early as 1500 B.C. and by the Indians to 1400 B.C. 
 Sergioasffirtri40 Reported  Reversed  phase  high  performance  liquid 
chromatography determination of lipophilicity of furocoumarins relationship 
with DNA interaction.  
          Objective & Plan of work
OBJECTIVE
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Leucoderma  is  a  kind  of  skin  disorder  and  otherwise  known  as  “swetha 
kuttam” in Sanskrit.  It is non infectious disease which occurs due to the deficiency of 
melanin.  In normal condition melanin is produced by melanocytes.   Melanin is a 
complex brown polymer synthesised from amino acid L – Dopa (Dihydroxyphenyl 
alanine).  The initial part of melanin synthesis is catalysed by a copper containing 
enzyme  tyrosinase.   This  catalyzed  the  transformation  of  L –  DOPA to  tyrosine. 
Melanin synthesis is under pituitary control (Melanocyte Stimulating Hormone). 
Leucoderma can reflect in the mind, causing psychological fears, emotional 
upset, shame, and socio behaviourial changes by trying to avoid being in the public, 
attitude of others who insult by avoiding contact. These changes restrict their social 
behaviour and communications. There may also be fear of ugliness, fear of hereditary 
(infecting the generation), contagiousness, other diseases, cancer, etc. Psoralen is one 
of the drugs of choice for the treatment of Leucoderma over 237 Herbal Drugs. 
The dosage forms available in market are having severe side effects. 
In the literature survey it is clearly evident that Psoralen Microsponge drug 
delivery  system  (MDS)  is  not  yet  formulated  and  my  objective  is  to  formulate 
Psoralen  MDS as  a  topical  drug delivery system.  Since  it  is  non-irritating,  non 
mutagenic, non allergic, non toxic and also improves the patient compliance.
 The main objective of my project work is to Isolate the active constituent  
from   crude drug and convert it into Novel Drug Delivery System (Microsponge) to  
reduce the side effects occurs in available conventional dosage forms. (Psoralen and  
ultra violet A (PUVA) therapy). 
PLAN OF WORK  
The scheme of proposed work is as follows 
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Extraction and Isolation
 Extraction of Psoralen from seeds of Psoralea corylifolia – By Soxhlet 
Extractor.
 Isolation of Psoralen – By Column chromatography
 Identification of isolated products – By TLC, IR and NMR studies.
Preformulation studies
 Characterization  of Psoralen 
 Identification of Psoralen (Chemical Test)
 Absorption maxima of Psoralen
 Solubility of Psoralen
 Infrared study of Psoralen 
 Calibration Curve for Psoralen drug 
Fabrication and characterization MDS 
Fabrication of Microsponge Drug Delivery System 
 Polymerization method 
 Quasi emulsion solvent diffusion method 
Optimization of various parameters in Microsponge formulation
Characterization of Microsponge 
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 Particle size (SEM) and Shape
 Encapsulation  efficacy
Microsponge is incorporate in Gel base
Formulation of gel 
Characterization of Gel
 Drug content 
 pH 
 Viscosity
 Spreadibility 
 Tube extrudability 
In-vitro studies 
Skin irritation studies 
Stability studies
Drug & Excipient Profile 
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DRUG PROFILE41
PSORALEN
In  this  present  investigation,  Psoralen  was  effectively  delivered  as  a 
Microsponge for the treatment of leucoderma. Psoralen (also called Psoralene) is the 
parent  compound  in  a  family  of  natural  products  known  as  furocoumarins. It  is 
structurally related to  coumarin by the addition of a fused  furan ring, and may be 
considered as a derivative of umbelliferone. Psoralen occurs naturally in the seeds of 
Psoralea corylifolia, it is widely used in PUVA (Psoralen +UltraViolet A) treatment 
for psoriasis, eczema leucoderma and vitiligo.
Structure: 
Molecular formula:  
C11H6O3 
IUPAC Name: 
7H-furo [3, 2-g] benzopyran-7-one
Physical Characteristics: 
Brown color or colorless needles, odorless.
Molecular Weight: 
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186.17 g/mol
Melting Point: 
158-161 °C
Category:  Topical Pigmenting agent.
Solubility:
Very soluble in chloroform; soluble in ethanol (95%); sparingly soluble in ether.
Practically insoluble in light petroleum (boiling range 60°C to 80°C).
Identification 
A. Dissolve 1 mg in 5ml  ethanol and add 15ml of a mixture containing 43 
volume of water 5 volume of acetic acid and 3volume of propylene glycol a 
blue fluorescence is visible  under Ultra Violet light (365nm). 
B.   Dissolve 1 mg in 2ml of ethanol and add 0.1M sodium hydroxide a yellow 
fluorescence is visible under Ultra Violet light (365nm).
Mechanism of action. 42 
Exact mechanism of action in the process of melanogenisis is unknown.  The 
action depends upon the presence of functional melanocytes and their proliferation by 
the photoactivated Psoralen.
Pharmacokinetics  
Oral Psoralen is more than 95% absorbed from GI tract.
Adverse Effect  
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Overexposure to UV emission may cause severe soreness, redness, blistering 
or peeling of skin.  Swelling of feet, GI upset, nausea, headache and malaise.
Contraindications
 Jaundice, Avoid contact with eyelids, genitalia and lips.
Route of administration: 
Oral and Topical
Dose:
 0.6 to 0.7 mg per Kg per Day.
Use:
 Vitiligo, Leucoderma, Psoriasis and Photochemical probe in biological system42
ETHYL CELLULOSE 43
Name
Ethyl Cellulose
Synonyms 
Aquacoat ECD, Ethocel, Surelase and Aqualon
Chemical Name
Cellulose Ethyl Ether 
Empirical Formula
C12H25O6 [C12H22O5] n C12 H23O5
Description 
Ethyl cellulose is a tasteless, free flowing, white to light tan-colored powder.
Density (bulk)
0.4g/cm2 
Glass transition temperature
129 to 133°C 
Solubility 
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Ethyl cellulose is practically insoluble in Glycerin, Propylene glycol and Water. It is 
freely soluble in Chloroform, Ethanol 95%, Ethyl acetate, Methanol and Toluene. 
Functional Category
Coating agent, Flavoring agent, Tablet binder, Tablet filler and Viscosity increasing 
agent.
POLY VINYL ALCOHOL 43
Name
Poly Vinyl Alcohol
Synonyms 
Airvol, Vinyl alcohol polymer
Chemical Name
Ethanol, homopolyma 
Empirical Formula
(C2H4O) n
Molecular Weight
20,000 to 2, 00,000 
Description 
Occurs  an odorless, white to cream colored granular powder.
Melting point
228°C 
Solubility 
Soluble in water, insoluble in organic solvents.
Application in pharmaceutical formulation
PVA is used primarily in topical pharmaceutical ophthalmic formulation. It is used as 
a stabilizing agent for emulsion.  It is also used as viscosity increasing agent for 
various formulation such as in sustain release formulation for oral administration43
Extraction and Isolation
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EXTRACTIION44
Extraction  is  the process of removing or extracting  or separating of active 
constituents from the crude drugs by using suitable solvents such as water, alcohol, 
solvent  ether  etc.  This  is  the  basic  principle  involved in  extraction  process.   The 
active  ingredients  that  have  been  extracted  from  the  crude  drugs  are  known  as 
extractives and the preparation so obtained are known as extracts.     
Fig 2 Types of Extraction
      Extraction
   Percolation          Infusion             Decoction      Maceration   Digestion
I Simple percolation I simple maceration
II Percolation process II Maceration with 
    for contracted preparation    adjustment
III Continuous hot Percolation III Multiple maceration 
   
SOXHLET EXTRACTION 
The apparatus consists of boiling flask, soxhlet extractor and a condenser. The 
drug to be extracted is packed in a filter  paper and placed in the extractor.  The 
solvent is taken in the boiled flask. The flask is heated. The solvent is boiled and 
vapour arises from the solvent and enters in to the condenser through a side tube 
present in the condenser. 
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The condensed hot liquid falls  on the packed column of the drug and the 
active constituents are extracted.  
As more and more condensed solvent fall on the drug, the level of the solvent 
in the extractor and the syphon rises.  When the level of the solvent reaches the top 
of the syphon the solvent along with dissolved active constituents drips back into 
the flask from the extractor through the syphon.  
On further heating the vapours of the solvent arises from the flask while the 
soluble active constituent remains in it and the process is repeated.  Every time the 
solvent  drips into the flask from the extractor,  the solvent carries  more and more 
active constituent.  The same process is repeated again and again until all the active 
constituents are extracted.  
EXTRACTION FOR SEED EXTRACT
100 gm of Psoralen seeds are extracted with ethanol under 60 to 80°C by 
continuous  hot  percolation  process  using  Soxhlet  apparatus.  After  completion  of 
extraction. The solvent was removed by distillation under reduced pressure.  Brown 
residue was obtained.  The residue is then stored in a desiccator.
   
ISOLATION OF PSORALEN FROM CRUDE BY COLUMN 
CHROMATOGRAPHY45                
Principle of chromatography
Chromatography techniques  are used to separate molecules on the basis of 
difference of size, shape, mass, charge, solubility and adsorption properties. The term 
chromatography is derived from the Greek meaning coloured writing and was first 
used  by the  Russian  botanist  Tswett  to  describe  the  separation  of  coloured  plant 
pigments on a column of alumina. There are many different types of chromatography 
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but  they  all  involve  interactions  between  three  components:  the  mixture  to  be 
separated, a solid phase and a solvent. 
The magnitude of these interactions is dominant in ion exchange 
chromatography whereas the solute-solvent interaction is more important in partition 
chromatography.
A brief introduction is given to the theory and practice of these techniques but 
not all compounds behave exactly as predicted on theoretical grounds and the best 
conditions for a particular separation often have to be found by practice.
Tab 3 Different techniques of chromatography
 Chromatographic separations can be carried out on a column of material and 
this is the method used for the isolation and preparation of compounds, alternatively, 
separations can be made in one or two dimensions on paper or a thin layer and these 
techniques are used for analytical work 
General procedure for running a flash column
Technique Solute Solid phase Solvent
Gel filtration Size and 
shape
Hydrated gel Usually aqueous
Adsorption 
chromatography
Adsorption Adsorbent usually inorganic 
material
Non-polar
Partition 
chromatography 
Solubility Inert support Mixture of polar and 
non-polar solvents
Ion exchange 
chromatography
Ionization Matrix with ionized groups Aqueous buffer
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Decide on a solvent system and on the quantity of silica
Run TLC’s to find a solvent system which will give a good separation of the 
components of the mixture,  and a Rf value of ca. 0.2-0.3 (usually start with ethyl 
acetate – petroleum ether mixtures). If spots are running close together, an Rf value of 
0.2-0.3 at the mid point is normally satisfactory.  But if they are well separated,  a 
solvent which puts the lower spot at Rf 0.2-0.3 will usually work. If we know which 
spot we are most interested in, try to bias our judgment towards this. There are often 
irrelevant impurities, which are either very polar or very non-polar and these can be 
largely ignored.  
We should try to use as little silica as possible since it is quite expensive.  Where 
the component you require is well separated from other component, as a ratio of Ca 
20:1 (silica: mixture) should be sufficient.  for more difficult separation up to 100:1 
ratio  can  be  used  (with  a  ratio  100:  spots  that  are  touching  on  TLC should  be 
separable in the appropriate solvent system).  an important fact to remember for all  
chromatographic  separations  is  that  the  more  spots  there  are  in  the  mixture,  the 
greater the ratio of silica for each individual separation.  Thus we normally require 
less  silica  to  separate  a  3spot  mixture,  than  for  a  2  spot  mixture  having  similar 
separations.  it is in this first step of the procedure that the greatest skill and judgment  
is required and careful attention should be paid to that TLC 's. With experience, the 
appropriate column and solvent to choose will become almost instinctive.  
Choose and prepare the column
Weigh out the required quantity of silica in a conical flask and make it into a 
mobile slurry with some of the chosen solvent.  Choose a column which will fill to 
about 18cm with the amount of silica being used (it is useful to mark columns once 
we know how much they hold).  To plug the bottom of the column roll a piece of 
cotton wool between the fingers so that it is wider than the column outlet; connects 
the column to a low vacuum line with the tap closed: drop the cotton wool ball to the 
bottom of the column, then open the tap. This is the most reliable way to insert the 
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plug.   Mount  the  column  vertically  using  a  clamp stand,  pour  about  8cm of  the 
solvent in and then carefully sprinkle a layer of fine sand (ca, 1mm), to cover the 
plug.   Very carefully add the silica slurry to the column,  in small  portions, via a 
powder funnel. Between each portion, pressurize the column to pack down the silica 
and remove excess solvent. Be careful not to allow the solvent to drop below the level 
of the top of the silica.
When all the silica has been loaded, leave to good head of solvent on top of it 
and sprinkle in enough sand to cover the surface of the silica evenly (ca. 1mm). Then 
force the excess solvent through the column until there is just a small layer left above 
the sand. There should now be a flat layer of silica covered by a thin and even layer 
of sand.
Load the sample
Dissolve the sample in the minimum amount of solvent, preferably the same 
solvent that we intend to run the column in (if this is not possible as is often the case, 
dissolve the sample in a small amount of dichloromethane). Keep a TLC sample of 
the sample mixture to compare with the column fractions.  Load the solution onto the 
top of the column, very carefully, using a Pasteur pipette to drip it around the walls of 
the column, just above the sand. Caution must be taken not to disturb the layer of 
sand.  Repeat  the  procedure  using  the  minimum  quantity  of  solvent  to  rinse  any 
remaining sample from the flask.  Once all the solution has been added allow the 
level of liquid to drop so that the top of the sand is just starting to dry.
Add the solvents 
Add the solvent to the top of the column, very carefully at first, again using a 
Pasteur  pipette to drip solvent around the walls of the column just above the sand, 
and taking care not to disturb the sand. Once a head of solvent is present, more can be 
poured in carefully from a beaker. Attach a solvent reservoir to the top of the column 
and secure it using a Rodaviss collar of elastic bands (Bibby clipps are not strong 
enough), and fill with solvent.
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Run the column  
Connect  the flash adapter  to  the top  of  the reservoir  and secure  it.  Apply 
pressure to give a fast solvent flow rate and collect fractions continuously. It is very 
important to maintain a fast flow rate through the column-the solvent should run, 
rather  than  drip!  A  slow  flow  rate  causes  reduced  resolution  NOT  improved 
separation. The size of fractions will depend mainly upon the size of the column and a 
rough guide,  they should be in  ml  about  half  the  weight  of  silica  (i.e.  for  a  30g 
column you should collect ca. 15ml; fractions). It is a myth that we get less mixtures 
by collecting smaller fractions- the mixture simply appears in more tube and leads to 
a good deal of extra work. You may feel safer collecting relatively small fractions at 
first, but as we become more experiences we will tend to collect larger fractions and 
thus considerably lower the amount of time we spend on chromatography.  Always be 
careful  note  to  let  the column run dry.   Monitor  the column fraction  by running 
TLC’S whilst the column is running (2 to 3 spots per plate is usually a convenient 
amount).  We should have time to apply a spot of the previous fraction to a TLC plate 
whilst the present fraction’s collection. 
PROCEDURE FOR PSORALEN SEED EXTRACT
About 45 gm of silica gel (60-120) mesh was loaded in to the glass column using 
hexane as the solvent by wet packing method.  1.5 gm of the crude Psoralen seed 
extract was mixed with double the amount of silica gel in a separate Petri dish using 
Dichloromethane as the solvent.  The powdered slurry of drug was passed in to the 
column and the fractions were eluted using the following solvent ration each fraction 
was collected with the volume of 20 ml.
Tab 4 Solvent System of Column Chromatography
Fraction No Solvent Ratio
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1 5% Ethyl Acetate: 95% Hexane
2 10 % Ethyl Acetate: 90 % Hexane
3 20 % Ethyl Acetate:80 % Hexane
4 30 % Ethyl Acetate: 70 % Hexane
5 40 % Ethyl Acetate: 60 % Hexane
6 50 % Ethyl Acetate: 50 % Hexane
7 60 % Ethyl Acetate: 40 % Hexane
8 70 % Ethyl Acetate: 30 % Hexane
9 80 % Ethyl Acetate: 20 % Hexane
10 90 % Ethyl Acetate: 10 % Hexane
11 100 % Ethyl Acetate
12 90 % Ethyl Acetate: 10 % Chloroform 
13 80 % Ethyl Acetate: 20 % Chloroform
14 70 % Ethyl Acetate: 30 % Chloroform
15 60 % Ethyl Acetate: 40 % Chloroform
16 50 % Ethyl Acetate: 50 % Chloroform
17 40 % Ethyl Acetate: 60 % Chloroform
18 30 % Ethyl Acetate: 70 % Chloroform
19 20  % Ethyl Acetate: 80 % Chloroform
20 10 % Ethyl Acetate: 90 % Chloroform
21 100 % Chloroform
22 90 % Chloroform: 10 % Ethanol 
23 80 % Chloroform: 20 % Ethanol
24 70 % Chloroform: 30 % Ethanol
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25 60 % Chloroform: 40 % Ethanol
26 50 % Chloroform: 50 % Ethanol
27 40 % Chloroform: 60 % Ethanol
28 30 % Chloroform: 70 % Ethanol
29 20  % Chloroform: 80 % Ethanol
30 10 % Chloroform: 90 % Ethanol
31 100 % Ethanol
THIN LAYER CHROMATOGRAPHY (TLC)
Principle
Thin  Layer  Chromatography  is  similar  to  paper  chromatography  but  the 
stationary phase is a finely divided sorbent spread as thin layer on a supporting flat 
plastic, aluminum and glass plate.  Solutes migrate through the stationary phase at 
rate determined by their  distribution ratio,  those with the large values moving the 
least if at all, while those with the smaller values moving with the advancing mobile 
phase/solvent front.
Application of the extract for separation
The extract of elute fraction from the column was taken in a capillary tube and 
it was spotted on a TLC  plate 2cm above its bottom most solution for application 
were between 0.1 to 1% strength.  The starting points equally sized as far as possible 
and had a diameter ranging from 2-5 millimeter.  
The  fractions  collected  from column  were  simultaneously  by  analyzed  by 
Thin  Layer  Chromatography  (TLC)  using  silica  gel  coated  by  hand.   The  pure 
compounds were identified from TLC using Iodine Chamber method.  Similar pure 
compound were mixed together and the fraction was ready for characterization by 
Infra Red spectrometer and Nuclear Magnetic Resonance.  Before characterization of 
component the solvent was removed by evaporating in vacuum oven.
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PURE COMPONENT OF PSORALEN EXTRACT RESULT
The  most  biological  active  prominent  pure  component  was  isolated  from 
column chromatography and it was identified as fraction 10-14.  After the component 
is characterized by IR, NMR.
ELUTION46
Tab 5 Solvent System of TLC
Plates No Fraction with crude Mobile Phase Ratio
1 1-3 30% Ethyl Acetate : 70% Hexane
2 4-6 60 % Ethyl Acetate : 40 %Hexane
3 7-9 75 % Ethyl Acetate :25 % Hexane
4 10-11 85 % Ethyl Acetate : 15 % Hexane
5 12-14 40 % Chloroform : 60 % Ethyl Acetate
6 15-17 60  % Ethyl Acetate : 40 % Chloroform
7 18-19 40 % Ethyl Acetate : 60  % Chloroform
8 20-21 80 % Ethyl Acetate : 20 % Chloroform
9 22-26 75 % Chloroform : 25 % Ethanol
10 25-27 55 % Chloroform : 45 % Ethanol
11 28-30 75 % Ethanol : 25 % Chloroform
12 31-33 100 % Ethyl acetate
Infrared (IR) Spectral Assignment: 
Infrared  spectrum  of  any  compound  or  drug  gives  information  about  the 
groups present in that particular compound.  IR spectrum of Psoralen was taken out 
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on FTIR (Perkin Elmer  Spectrum Rx-1)  spectrophotometer.   Various  peaks  in  IR 
spectrum were interpreted for the presence of different groups51   
Nuclear Magnetic Resonance (NMR)
One useful feature of NMR spectra is that, the more protons there are of a 
given type, the stronger is the peak in the spectrum.  In fact, the area under the peak 
gives us a measure of how many protons are involved.  By using scale of chemical 
shift we could actually count the number of protons.  Fortunately the measurement of 
the area is done automatically by the spectrometer.  
The  confirmation  of  Psoralen  has  been  carried  out  by  NMR spectrometer 
(Bruker NMR) using deuterated chloroform as a solvent.    The final structure of the 
isolated  compounds  may  posse’s  basic  nucleus  Enol  (Eu  IV),  Furan  (Eu  II)  as 
confirmed by delta values in  parts per million (ppm) of  1H  NMR spectrum Eu II. 
The result obtained were presented table 5 for Eu II. 47 – 50
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Fig 3 TLC Analysis of Different Fractions (III & IV)
Fig 4 TLC Analysis of Different Fractions (V, X& XI)
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Tab 6 Interpretation of IR Spectrum
Functional 
group
Wave number Cm-1 (Centimeter)
Crude extract Sample II Sample IV Ethyl Cellulose
- OH 3435.97 3421.85 3397.20 ------
-CH- 2927.15 2928.15 2975.91
2
925.54
- CH2 2365.34 2362.38 2360.57 2362.36
- C6H5 ------ 1692.16 ------ 1635.45
C=O 1626.88 1613.03 1649.92 1740.93
C=C 1396.23 1423.68 1390.16 1384.56
-C-O-C 1111.23 1179.05 ------ 1113.21
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Tab 7 Interpretation of NMR Eu II
Structure Delta values in  Parts Per 
Million(ppm)
a = 7.52
b = 6.66
c = 7.49
d = 7.13
e = 7.19
f = 7.42
a = 6.45
b = 7.80
c = 7.63
d = 7.22
e = 7.45
f =7.20
a = 7.38
b = 6.30
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Fig 5 Infra Red spectrum of Crude Extract of Psoralen
Spectrum Name: Sample = Crude Ext of Psoralen.sp 
Sample = Crude Ext of Psoralen.pk
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FTIR SPECTRUM
Spectrum Name: Sample II.sp 
Date: 11/28/2007
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Fig 6 Infra Red spectrum of sample II
Fig 7 Infra Red spectrum of sample IV
Fig 8 Infra Red spectrum of Ethyl Cellulose
Spectrum Name: Sample IV.sp 
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Spectrum Name: Sam = Ethyl Cellulose.sp 
Sam = Ethyl Cellulose.pk
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Fig 9 NMR Spectrum of isolated compound Eu IV
Fig 10 NMR Spectrum of isolated compound Eu II
Chapter – 6 Preformulation Studies 
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PREFORMULATION STUDIES
The physiochemical properties of drug plays an important role in the 
designing of the drug delivery systems.  Hence, Preformulation studies are essential 
to characterize drug for proper designing of the drug delivery systems.  The 
Preformulation studies, which were performed in this project work, include 
identification of drug (chemical test, UV maxima) and solubility analysis.
DRUG IDENTIFICATION36
 IR spectra and Absorption maxima identified the isolated of drug from crude 
extract. (I.P (Indian Pharmacopeia) 1996)  
Chemical Test
A. 1 mg isolated drug was dissolved in 5ml ml ethanol and then added 
with 15ml of a mixture containing 43 volume of water 5 volume of 
acetic acid and 3volume of propylene glycol. A blue fluorescence was 
visible under Ultra Violet light (365nm). 
B.   1 mg isolated drug was Dissolved in 2ml of ethanol and then added 
with  0.1M  sodium  hydroxide.   A  yellow  fluorescence  was  visible 
under Ultra Violet light (365nm).
Inference:
 It showed blue fluorescence and yellow fluorescence under Ultra Violet light 
(365nm).  This confirms the drug was Psoralen.
Absorption Maxima
Drug molecule  in  solution  when exposed to  light  in  the  visible/ultraviolet 
region of the spectrum absorbs light of particular wave length depending on the type 
of electronic transition associated with the absorption.
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The drug solution  (1mg/ml)  in  phosphate  buffer  pH 6.8 was taken in the cuvette 
scanned in  the range of  230 to 400 nm in  a  UV spectrophotometer.   It  exhibits 
maxima at 247 nm.  Therefore, all the further measurements were taken at 247 nm36 
Fig 11 Absorption maxima of Psoralen
Solubility 
Studies 
The  spontaneous  interaction  of  two  or  more  substance  to  form homogeneous 
molecular dispersion is called as solubility.  The solubility of Psoralen was studied in 
various solvents.  Psoralen (10mg) was suspended separately in a 10 ml of different 
solvents at room temperature in tight closed test tube and shaken on wrist action.  The 
solubility of Psoralen in various solvents are follows 
A. Very soluble in chloroform; soluble in ethanol (95%); sparingly soluble in 
ether
B. Practically insoluble in light petroleum.
Calibration Curve of Psoralen
Preparation of phosphate buffer pH 6.8
Phosphate buffer pH 6.8 was prepared according to the following methods 
(I.P.1996).  Disodium hydrogen phosphate (6.8g) was dissolved in 500ml of distilled 
water and sodium hydroxide (1g) was dissolved in distilled water from that 224ml of 
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solution was taken and added with above solution and volume was made up to 1 liter 
with distilled water.  The pH was adjusted to 6.8 prior to quantitative estimation28.
Preparation of Calibration Curve of Psoralen in Phosphate buffer pH 6.8
Accurately  weighed  quantity  (100mg)  of  Psoralen  was  transferred  into  a 
100ml volumetric flask and dissolved in small amount of buffer pH6.8 and made up 
the volume with same buffer to make the standard stock solution of 1mg/ml.  From 
the stock 1ml was taken in 10 ml volumetric flask and made up the volume with the 
buffer, from this solution 0.5ml to 3ml solution was transferred to 10 ml volumetric 
flask and made up required volume with buffer and resulting concentration ranging 
from 5 to 30 micrograms per ml. The absorbance of these solutions was determined at 
247 nm using UV spectrophotometer.  
The  standard  curve  was  constructed  between  the  absorbance  and 
concentration.  This standard curve was linearly regressed and statistical parameter 
related it was derived.
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Fig 12 Calibration Curve of Psoralen 
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Tab 8 Calibration curve of Psoralen 
S. NO Concentration (µg/ml) Absorbance at 247nm
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1 5 0.069
2 10 0.120
3 20 0.244
4 30 0.330
5 40 0.457
r = 0.9979  a= 0.0116  b = 0.011
           Fabrication & Characterization 
FABRICATION AND CHARACTERIZATION OF MDS 
Psoralen Micro sponges were prepared by Quasi emulsion solvent diffusion 
method. In this method, the organic internal phase containing  Psoralen (50mg) and 
Ethyl Cellulose in 20 ml Dichloromethane was gradually added into 60 ml distilled 
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water which contained different concentration(0- 2 %) of Poly Vinyl Alcohol (PVA) 
as  emulsifying  agent.  The mixture  was stirred  for  6 hours,  at  25 °C.  The formed 
Microsponge were filtered and washed with distilled water before being tray-dried at 
room temperature.  For  the  evaluation  of  the  effect  of  drug:  polymer  ratio  on the 
physical  characteristics  of  Microsponge,  different  weight  ratios  of  drug  to  Ethyl 
Cellulose (EC) (1:0.5, 1:1, 1:1.5) were employed. In all these formulations, the total 
amount of drug was kept constant. To optimize the particle size, size distribution and 
the drug release from the Microsponge, an individual formulation was selected and a 
series of the Microsponges were prepared using different stirring rates. However, for 
optimizing  the  preparation  method  and  the  characteristics  of  the  prepared 
Microsponge were evaluated10.
Optimization of various parameters 
During  the  Microsponge  preparations,  the  variables  such  as  amount  of 
polymer,  emulsification agent, stirring time, and stirring speed were optimized for 
getting spherical shape Microsponge with maximum drug encapsulation efficacy.
Tab 9 Optimization of various parameter of the formulation 
Formulation
& process 
variables
Drug 
(mg)
Polymer
(mg)
PVA
(%)
Stirring
Time
(hours)
Stirring
Speed
(rpm)
Encapsulation 
efficacy 
± S.D. (%)
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Polymer (EC) 50 25 2 6 Medium 53.13±1.5
50 50* 2 6 Medium 70.52±0.8
50 75 2 6 Medium 62.68±1.9
Emulsification 
agent (PVA)
50 50 without 6 Medium --
50 50 1 6 Medium 48.30±0.9
50 50 2* 6 Medium 70.52±0.8
Stirring time 50 50 2 2 Medium 55.76±1.2
50 50 2 4 Medium 59.20±0.8
50 50 2 6* Medium 70.52±0.8
Stirring speed 50 50 2 6 Slow 49.45±0.4
50 50 2 6 Medium* 70.52±0.8
50 50 2 6 High 34.24±0.9
* Optimum parameter, the values are mean ±SD (n = 3)
Tab 10 Optimized formula for MDS 
Compatibility Study by Differential Scanning Colorimeter (DSC)
Fig 13 DSC of Psoralen
Formulation 
code
Polymer 
concentration 
(mg)
Drug 
concentration 
(mg)
Stirring 
speed
Stirring 
time 
(hours)
Encapsulation 
efficacy  
± S.D. (%)
P  -  MDS  2 
(1:1) ratio 
50 50 Medium 6 70.52
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Fig 14 DSC of Ethyl Cellulose
Fig 15 DSC of P – MDS 2
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Characterization of MDS
MORPHOLOGICAL STUDY
Prepared MDS was characterized by Scanning Electron Microscopy (Hitachi 
model S- 30000H, Japan).  The MDS was coated with Gold-Palladium alloy.  After 
coating the scanning was taken to determine the particle size and Shape. (Fig 16-19)
DRUG ENCAPSULATION EFFICACY
The amount  of Psoralen encapsulated in MDS was estimated  by using the 
following formula.
Amount of drug released from the lysed MDS
Encapsulation efficacy (%) =  
------------------------------------------------------------
 Amount of drug initially taken to prepare MDS
Fig 16 SEM PHOTOGRAPHY OF P – MDS 1 (1:0.5)
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Fig 17 SEM PHOTOGRAPHY OF P – MDS 2(1:1)
 
Fig 18 SEM PHOTOGRAPHY OF P – MDS 3(1:1.5)
81
Fig 19 Shape of the Microsponge
MDS INCORPORATED IN GEL BASE
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Prepared Microsponges were incorporated in to 1% carbopal 934 Gel base to 
form a gel and evaluated the following parameters
 pH
 Viscosity
 Drug content analysis
 Spreadability
 Extrudability
pH
pH of the formulation was measured by using a digital type pH meter (Elico 
Make) by dipping the electrode completely in the Microsponge gel so as to cover the 
electrode and read out the pH.
Viscosity
The viscosity of the prepared gel was measured using Brookfield viscometer 
(RV 1 Brookfield Viscometer) at a controlled temperature.
Drug content 
A specific  quantity (1.0gm) of Psoralen Microsponge gel was dissolved in 
distilled water and the solution is filtered through the Whatman filter  paper.   The 
absorbance of the solution was measured by UV spectrophotometer (Shimadzu 1700) 
at 247nm against blank.  
Spreadability 
One of the criteria for a gel   to meet ideal quality is that it should possess  
good spreadability.  About 1gm of Psoralen Microsponge gel was weighed and kept 
at the center of the glass plate (10x10 cm) and another glass plate is placed over it 
carefully.  2 kg weight was placed at the center of the plate (avoid sliding of the gel). 
The diameter of the gel in cms, after 30 minutes was measured.
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Tube extrudability  
It  is  a  useful  empirical  test  to  measure  the  force  required  to  extrude  the 
material from a tube.  The formulation under study was filled in a tube with nasal tip 
of 5 mm opening tube extrudability was then determined by measuring the amount of 
gel extruded through the tip when a pressure was applied on the tube gel.
Tab11 Evaluation parameter of P-MDS in Gel base 
G – Good   E – Excellent   P-MDS G - Psoralen Microsponge Drug Delivery System 
                   In vitro diffusion studies 
Cellophane Membrane Treatment
Formulation 
code
pH Viscosity 
Centipoises 
(Cps)
Drug 
content 
(%)
Spreadabilit
y
Centimeters
(Cm)  
Extrudability
(Grade)  
P-MDS – 1G 6.72 42500 93.04 5.4 E
P-MDS – 2G 6.80 41000 90.16 5.2 E
P-MDS – 3G 6.56 42000 85.52 5.3 G
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Cellophane membrane was boiled in the distilled water for 1 hr and washed 
with fresh distilled water for three times and kept in ethanol for 24 hrs.  It was washed 
with distilled water and treated with 0.3% sodium sulphite and soaked in distilled 
water for 2min at 60°C followed by acidified with 0.2% sulphuric acid.  Finally the 
membrane was dipped in boric buffer (pH 9) till it is used for permeation study. 52 
Drug Permeation Studies
The  in  vitro release  rate  of  Psoralen  were  evaluated  by  open  ended  tube 
through the cellophane membrane method using PB pH6.8 as diffusion medium up to 
12 hours studies.  The cellophane membrane is tided in one end of the tube and then 
immersed in the receptor compartment containing 200ml of PB pH6.8. Which was 
stirred at medium speed and maintained at 37°C±2°C.  Samples were withdrawn at 
regular time intervals and the same volume was replaced by fresh diffusion medium. 
The  samples  were  analyzed  using  UV  –  visible  spectrophotometer  (Shimadzu 
UV1700) set at 247 nm.  
Tab 12 Diffusion Profile of P – MDS 1G
Tab 13 Diffusion Profile of P – MDS 2G
S. No Time  in hours (hrs)
Cumulative Percentage
drug release   P-MDS1G
1 0 0
2 0.25 2.68
3 0.5 3.97
4 0.75 4.08
5 1 8.20
6 2 15.14
7 3 29.88
8 4 34.89
9 5 48.15
10 6 50.86
11 8 54.35
12 10 54.86
13 12 57.52
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Tab 14 Diffusion Profile of P – MDS 3G
Tab 15 Comparative diffusion profile of P – MDS
S. No Time  in hours (hrs)
Cumulative Percentage
 drug release   P-MDS2G
1 0 0
2 0.25 1.27
3 0.5 2.21
4 0.75 3.65
5 1 4.05
6 2 11.25
7 3 14.71
8 4 21.05
9 5 29.09
10 6 42.96
11 8 54.64
12 10 58.68
13 12 61.63
S. No Time  in hours (hrs)
Cumulative Percentage
drug release  P-MDS3G
1 0 0
2 0.25 0.62
3 0.5 0.94
4 0.75 1.34
5 1 2.17
6 2 3.59
7 3 9.74
8 4 16.95
9 5 29.27
10 6 35.94
11 8 42.24
12 10 44.55
13 12 49.45
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Fig 20 Diffusion Profile of P – MDS 1G 
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S. No Time  in 
hours (hrs)
Cumulative percentage drug release  
P-MDS1 P-MDS2 P-MDS3
1 0 0 0 0
2 0.25 2.68 1.27 0.62
3 0.5 3.97 2.21 0.94
4 0.75 4.08 3.65 1.34
5 1 8.20 4.05 2.17
6 2 15.14 11.25 3.59
7 3 29.88 14.71 9.74
8 4 34.89 21.05 16.95
9 5 48.15 29.09 29.27
10 6 50.86 42.96 35.94
11 8 54.35 54.64 42.24
12 10 54.86 58.68 44.55
13 12 57.52 61.63 49.45
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Fig 21 Diffusion Profile of P – MDS 2G 
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Fig22 Diffusion Profile of P – MDS 3G 
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Fig 23 Comparative diffusion profile of P – MDS
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       Skin Irritation Test 
SKIN IRRITATION STUDIES53 
Skin irritation test was performed on 3 rabbits weighing between 2 – 3.5 kg. 
Adhesive USP was used as control. The Psoralen Microsponge gel was used as a test 
sample.  Test was conducted unbraided skin of rabbits.  The control  was placed on 
left dorsal surface of each rabbit, whereas test formulation were placed on identical 
side of the right dorsal surface of the rabbits, the gel formulation were removed after 
24  hours  with  the  help  of  an  alcohol  swab  and  skin  was  examined  for 
erythma/oedema.  
Tab 16 Skin Irritation Results
Formulation Skin Irritation
Psoralen in gel base +
P – MDS 2 G -
+ indicate edema, - indicate no edema
Inference:
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Compare to the formulation P – MDS 2G with Psoralen in gel base, 
Psoralen in gel base produced erythma and inflammation at the level of 2 millimeter 
after 24 hours studies.
Fig 24 Preparation of skin irritation test
Fig 25 Control for Skin irritation test (USP adhesive tap)
91
Fig 26 After 24 hours study with P – MDS 2 in Gel base
 
Fig 27 After 24 hours study with Psoralen in Gel base
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                      Stability Testing
STABILITY STUDIES
In pharmaceutical  sense,  stability  is  technically  defined  as  the  capacity  of 
particular formulation in a specific container or closure system, to remain within its 
physical,  chemical,  microbiological,  therapeutic  and  toxicological  specification. 
Durability of a product may be defined as the capability of a particular formulation in 
a  specific  container  to  remain  with  the  physical,  chemical,  microbiological, 
therapeutic and toxicological specification. Stability of Microsponge gel formulation 
on storage is of a great concern as it is the major resistance in the development of 
marketed preparations.  The prepared formulation was tested for stability on storing 
them at 4±1°C 25±2 °C and37± 5°C & RH (Relative Humidity) 75%
Formulation was stored in  gel  tube at  4±1°C 25±2  °C and 37±5  °C for a 
period of three months.  After one month and three months they were evaluated for 
the following parameters:
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 Appearance
 pH
 Drug content analysis
 Spreadability
Tab 17 Stability study data of formulation stored at 25±2 °C
Parameter
 Detected
                          Duration of Evaluation
Initial After
1month
After
3months
Appearance Good Good Good
pH 6.72 6.78 6.78
Drug Content (%) 90.88 89.36 89.36
Spreadability (cm) 5.4 5.4 5.2
Tab 18   Stability study data of formulation at 4±1°C  
Parameter
 Detected
                          Duration of Evaluation
Initial After
1month
After
3months
Appearance Good Good Good
pH 6.72 6.66 6.6
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Drug Content (%) 90.88 90.16 89.36
Spreadability (cm) 5.4 5.2 5.3
Tab 19   Stability study data of formulation stored at 37±5°C RH 75%
Parameter
 Detected
                          Duration of Evaluation
Initial After
1month
After
3months
Appearance Good Good Good
pH 6.72 6.78 6.70
Drug Content (%) 90.88 89.44 89.44
Spreadability (cm) 5.4 5.8 6.1
Stability  testing  were  carried  out  by  exposing  formulated  P–MDS  2G  at 
various temperature of 4±1°C, 25±2°C and 37±5°C for the period of three months. 
The results indicated that they are stable both physically and chemically at 4±1°C and 
25±2°C. In all these 3 temperature, there was no marked change in drug content, pH 
and physical appearance.  The spreadability showed a significant change at elevated 
temperature 37±5°C.  Since spreadability was increases with the decrease in viscosity 
of gel base.  Thus it is advisable to store at below 37±5°C.
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               RESULTS AND DISCUSSION
Leucoderma is a miserable acquired skin disorder making skin white due to 
loss of melanin pigment.  Different plants (237) were being used to treat this disorder. 
The drug of choice for this is Psoralen – isolated from Psoralea corylifolia.  In the 
present  study  Psoralen  is  considered  to  design  as  a  Microsponge  Drug  delivery 
System (MDS).  
ISOLATION AND IDENTIFICATION
Psoralen is extracted from Psoralea corylifolia plant seeds by using soxhlet 
extractor and isolated through column chromatography.  After isolation the isolated 
pure  compound  was  primarily  identified  by  Absorption  maxima,  IR spectroscopy 
(Infra Red) and confirmed by Nuclear  Magnetic  Resonance (NMR) study and the 
isolated product was brown colour powder, which is used for further work.
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The present work emphasis was conversion of crude drug in to Novel drug 
delivery system – Microsponge Drug delivery System (MDS).  The Novel system 
reduces the side effects which occur in the marketed product especially in Psoralen 
and Ultra Violet A (PUVA). 
The absorption maxima of Psoralen in phosphate buffer pH 6.8 was measured 
by UV- visible spectrophotometer against the blank and was found to be 247 nano 
meter (nm).  The result was shown in Fig 11.
Solubility  studies  of  Psoralen  in  different  solvent  at  room  temperature 
indicated that the drug was freely soluble in chloroform and soluble in ethanol.
OPTIMIZATION OF VARIOUS PARAMETERS
The  Microsponges  were  prepared  by  using  Quasi  –  Emulsion  Solvent 
Diffusion Method.  The various formulation parameters used in trial formula were
 Polymer concentration
 Emulsifying agent
 Stirring speed and Time
The quantity of polymer used in the preparation was 25 – 75 milligram (mg). 
The particle size increased due to increase in the concentration of the polymer.  The 
theoretical drug loading was kept constant but the amount of polymer was increased 
from 25 – 75 mg.  The encapsulation efficacy was higher with 50 mg of polymer and 
got desired size and shape. 
The concentration of the emulsifying agent Poly Vinyl Alcohol (PVA) from 0 
–  2  %  were  used  to  access  the  effect  on  the  formulation  characteristic.   The 
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formulation without PVA were not formed Microsponges.  When the concentration of 
PVA was 1 – 2% give required particle size range [5 – 300 micrometer (mm)] and the 
encapsulation efficacy was high.  The optimized concentration of PVA was found to 
be 2% in the formulation and hence it forms Microsponges with desired size.
At medium speed,  the Microsponges were produced of  desired range with 
maximum  encapsulation  efficacy.   At  low  speed  the  Microsponges  were  not  in 
uniform size and encapsulation efficacy was also less.  At higher speed the particle 
size was small with low encapsulation efficacy.
The stirring time was optimized to get desired shape and higher encapsulation 
efficacy.  The optimized stirring time was 6 hours.
Based on these three parameters formulation P – MDS 2 have desired size, 
shape and high encapsulation efficacy.  The results are shown in Table No 9.
COMPATIBILITY STUDY 
 Compatibility  study  was  accessed  by  Differential  Scanning  Colorimeter 
(DSC).  The results are shown in Fig 13 to 15.  It indicated that there is no chemical 
interaction between the drug, polymer and MDS.
The DSC thermograms of drug Peak at 142.24, Ethyl Cellulose polymer Peak 
at 264.90.  The thermograms had shown an endothermic peak at 151.6 and 251.46. 
The DSC thermograms indicated that there is no drug – polymer interaction in P –
MDS 2 formulation due to no change in the endothermic peak in the thermogram.
MORPHOLOGIAL STUDY
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Scanning Electron Microscopy (SEM) indicated that the Microsponges are in 
spherical, discrete particle with internal voids with a size range of 5 to 40 µm (micro 
meter).  The results are shown in Fig 16 to 19.
IN VITRO DIFFUSION STUDY
In vitro diffusion study was carried out using an artificial  membrane for a 
period of 12 hours. Comparative study of the diffusion profile of the drug from 3 
prepared formulations with various drug – polymer ratio are tabulated in  Tab 12 to 
15 and presented in Fig 20 to 23respectively
A maximum percentage of 61.63% was obtained from formulation P –MDS 
2G during 12 hours study.  Therefore the formulated P –MDS 2G was selected for 
further studies. 
SKIN IRRITATION TESTING
The skin irritation studies results are shown in Fig 24 to 27.  It revealed that 
the P – MDS 2G formulation do not cause any noticeable irritation or edema in rabbit 
skin compared to control (USP adhesive tap), but Psoralen in gel base carbopal 934 
which causes noticeable irritation and edema compared with control.
  This indicates that the P – MDS 2G was safe for topical application for treatment of  
Leucoderma.
STABILITY TESTING 
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Stability  testing  were  carried  out  by  exposing  formulated  P–MDS  2G  at 
various temperature of 4±1°C, 25±2°C and 37±5°C for the period of three months. 
The results indicated that they are stable both physically and chemically at 4±1°C and 
25±2°C. In all these 3 temperature, there was no marked change in drug content, pH 
and physical appearance.  The spreadability showed a significant change at elevated 
temperature 37±5°C.  Since spreadability was increases with the decrease in viscosity 
of gel base.  Thus it is advisable to store at below 37±5°C.
CONCLUSION
About 3 – 5% of the world populations are suffering from the skin disorder 
Leucoderma.   Psoralen  is  a  drug choice  for  treating  the  skin  disorder.   Psoralen 
Microsponges  were  prepared  by  Quasi  –  Emulsion  Solvent  Diffusion  Method 
utilizing Ethyl Cellulose as a polymer and incorporated in gel base.
The present work emphasis was conversion of crude drug in to Novel drug delivery 
system – Microsponge Drug delivery System (MDS).   The Microsponges  have a 
distinct advantage over the existing conventional dosage forms, for example PUVA 
therapy having severe side effects  like  skin -irritation,  mutagenic,  skin allergic, 
toxic and blisters etc.
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The prepared P – MDS G has achieved the objective of non – irritation, non –  
toxic and sustained release and thus improved patient compliance. 
Further studies will be carried out to determine the In Vivo characteristic 
P- MDS G.
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